Page last updated: 2024-11-06

colforsin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Colforsin is a synthetic diterpene that acts as a selective activator of adenylate cyclase, an enzyme that catalyzes the conversion of ATP to cAMP. cAMP is a second messenger involved in various cellular processes, including cell growth, differentiation, and metabolism. Colforsin has shown promising effects in preclinical studies for treating various diseases such as cancer, Alzheimer's disease, and heart failure. Its importance lies in its ability to modulate cAMP levels, which offers therapeutic potential for a wide range of conditions. Colforsin is studied to investigate its efficacy and safety as a potential therapeutic agent for these diseases. It is synthesized through a multi-step process involving a series of chemical reactions.'

Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
ColeusgenusA plant genus of the family Lamiaceae. The species of Coleus should be distinguished from PLECTRANTHUS BARBATUS - which is also known as Coleus forskohlii.[MeSH]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]

Cross-References

ID SourceID
PubMed CID47936
CHEMBL ID52606
CHEBI ID42471
SCHEMBL ID4928
MeSH IDM0358301

Synonyms (142)

Synonym
MLS001066384
smr000471881
MLS002695942
MLS002172462
HMS3267I16
c22h34o7
BRD-K09602097-001-04-5
m-410
boforsin
l-751362b
ocufors
hl-362
nsc-357088
D03584
colforsin (usan/inn)
forskolin, from coleus forskohlii, >=98% (hplc), powder
colforsina [spanish]
colforsine [french]
1h-naphtho(2,1-b)pyran-1-one, dodecahydro-5-(acetyloxy)-3-ethenyl-3,4a,7,7,10a-pentamethyl-6,10,10b-trihydroxy-, (3r-(3-alpha,4a-beta,5-beta,6-beta,6a-alpha,10-alpha,10a-beta,10b-alpha))-
l 75 1362b
7-beta-acetoxy-8,13-epoxy-1-alpha,6-beta,9-alpha-trihydroxylabd-14-en-11-one
hl 362
einecs 266-410-9
nsc 357088
nsc 375489
(3r,4ar,5s,6s,6as,10s,10ar,10bs)-dodecahydro-5,6,10,10b-tetrahydroxy-3,4a,7,7,10a-pentamethyl-3-vinyl-1h-naphtho(2,1-b)pyran-1-one 5-acetate
colforsin [usan:inn]
colforsinum [latin]
1h-naphtho(2,1-b)pyran-1-one, 5-(acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-, (3r-(3alpha,4abeta,5beta,6beta,6aalpha,10alpha,10abeta,10balpha))-
BCBCMAP01_000132
BIO1_000932
BIO1_000443
BIO1_001421
CHEBI:42471 ,
(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxododecahydro-1h-benzo[f]chromen-5-yl acetate
colforsina
colforsinum
colforsine
1h-naphtho(2,1-b)pyran-1-one, 5-(acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-
nsc-375489
nsc375489 ,
SMP1_000128
MLS001333256
MLS001333255
FOK ,
66575-29-9
C09076
colforsin
coleonol
forskolin ,
[(3r,4ar,5s,6s,6as,10s,10ar,10bs)-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyl-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate
1h-naphtho[2,1-b]pyran-1-one, 5-(acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-, (3r,4ar,5s,6s,6as,10s,10ar,10bs)-
forskolin, for use in molecular biology applications
DB02587
NCGC00024996-03
7beta-acetoxy-8,13-epoxy-1alpha,6beta,9alpha-trihydroxylabd-14-en-11-one
coleonolk
NCGC00024996-02
MOLMAP_000021
[3r-(3a,4ab,5b,6b,6aa,10a,10ab,10ba)]-5-(acetyloxy)-3-e thenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1h-naphtho[2,1-b]pyran-1-one
inchi=1/c22h34o7/c1-8-19(5)11-14(25)22(27)20(6)13(24)9-10-18(3,4)16(20)15(26)17(28-12(2)23)21(22,7)29-19/h8,13,15-17,24,26-27h,1,9-11h2,2-7h3/t13-,15-,16-,17-,19-,20-,21+,22-/m0/s1
ohcqjhsobutrhg-kgghgjdlsa-
CHEMBL52606 ,
l-75-1362b
[(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate
MLS-0318096.0001
cid_47936
bdbm50010261
LMPR0104030004
NCGC00024996-04
NCGC00024996-06
NCGC00024996-05
tox21_302399
cas-66575-29-9
dtxcid6020484
NCGC00255526-01
dtxsid8040484 ,
tox21_110940
HMS2235C17
5-(acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1h-naphtho(2,1-b)pyran-1-one
forslean
66428-89-5
1f7a44v6ou ,
unii-1f7a44v6ou
REGID_FOR_CID_47936
(3r,4ar,5s,6s,6as,10s,10ar,10bs)-dodecahydro-5,6,10,10b-tetrahydroxy-3,4a,7,7,10a-pentamethyl-3-vinyl-1h-naphtho[2,1-b]pyran-1-one 5-acetate
colforsin [usan]
forskolin [vandf]
colforsin [inn]
colforsin [who-dd]
forskolin (constituent of forskohlii) [dsc]
colforsin [mi]
colforsin [mart.]
forskolin [usp-rs]
S2449
(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-dodecahydro-1h-naphtho[2,1-b]pyran-5-yl acetate
gtpl5190
CS-1454
HY-15371
AM81249
SCHEMBL4928
NCGC00177971-03
tox21_110940_1
OHCQJHSOBUTRHG-KGGHGJDLSA-N
[3r-(3?,4a?,5?,6?,6a?,10?,10a?,10b?)]-5-(acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1h-naphtho[2,1-b]pyran-1-one
Q-200888
timsaponin-c
[3r-(3
HB1348
(3r,4ar,5s,6s,6as,10s,10ar,10bs)-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1h-benzo[f]chromen-5-yl acetate
AC-33150
AKOS024456384
F0855
mfcd00082317
forskolin, analytical standard
sr-01000597378
SR-01000597378-1
forskolin, united states pharmacopeia (usp) reference standard
[(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl]acetate
Q412747
HMS3676G19
AS-17443
HMS3412G19
NCGC00024996-34
CCG-268774
A850885
coleonol;7beta-acetoxy-8,13-epoxy-1alpha,6beta,9alpha-trihydroxylabd-14-en-11-one
NCGC00024996-07
forskolin - 20%
forskolin - 40%
XF165212
XF165211
forskolin - 10%
XF165210
EX-A5963
HY-15371G
forskolin (gmp)
CS-0622781
forskolin- bio-x
BF164487
(-)-forskolin
Z1395264745

Research Excerpts

Overview

Colforsin daropate is a water-soluble derivative of forskolin. It directly stimulates adenylate cyclase, unlike the catecholamines.

ExcerptReferenceRelevance
"Colforsin daropate is a recently developed water-soluble derivative of forskolin that directly stimulates adenylate cyclase, unlike the catecholamines. "( Cardiovascular and adenylate cyclase stimulating effects of colforsin daropate, a water-soluble forskolin derivative, compared with those of isoproterenol, dopamine and dobutamine.
Hashimoto, K; Nakamura, Y; Satoh, Y; Sugiyama, A; Takahara, A; Yoneyama, M, 2002
)
2
"Colforsin daropate is a novel and potent water-soluble forskolin derivative."( Intravenous colforsin daropate, a water-soluble forskolin derivative, prevents thiamylal-fentanyl-induced bronchoconstriction in humans.
Imanaga, K; Inoue, T; Ogawa, R; Ogura, A; Shiga, T; Wajima, Z; Yoshikawa, T, 2002
)
1.41

Treatment

ExcerptReferenceRelevance
"Pretreatment with colforsin caused a dose-dependent inhibition in the elevation of intracellular free calcium (monitored by fura-2 fluorescence), which was observed in human PMN stimulated with FMLP."( Effect of colforsin on human neutrophil superoxide production and intracellular calcium mobilization.
Furui, H; Satake, T; Suzuki, K; Takagi, K, 1989
)
1

Toxicity

ExcerptReferenceRelevance
" Recently, there have been several reports that A beta has toxic effects on both cultured neurons and in the brain."( A new compound (AZ36041) promotes the survival of the neurons and reduces neurotoxicity of Alzheimer's beta-amyloid protein.
Aratake, H; Endo, T; Hasegawa, Y; Kitaguchi, N; Morikawa, A; Ogawa, K; Sugimoto, E, 1995
)
0.29
" All of these animals also survived with no apparent adverse effects."( Reversal of propranolol blockade of adrenergic receptors and related toxicity with drugs that increase cyclic AMP.
Alleva, FR; Balazs, T; Joseph, X; Vick, JA; Whitehurst, VE; Zhang, J, 1999
)
0.3
" We found that toxic lipids relevant to three different LSDs disrupt multiple lysosomal and other cellular functions."( Lysosomal Re-acidification Prevents Lysosphingolipid-Induced Lysosomal Impairment and Cellular Toxicity.
Folts, CJ; Mayer-Pröschel, M; Noble, M; Pröschel, C; Scott-Hewitt, N, 2016
)
0.43
"Our results show that the use of the current version of the SPOM system may have adverse effects on oocytes and blastocysts calling for optimized protocols for improving oocyte competence."( Simulated physiological oocyte maturation has side effects on bovine oocytes and embryos.
Callesen, H; Fontes, PK; Hyttel, P; Kadarmideen, HN; Nogueira, MFG; Pedersen, HS; Pihl, M; Razza, EM; Stroebech, L, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
"It is proposed the data obtained by these in vitro experiments can be used to investigate the in vivo pharmacodynamic of A, full and partial agonists."( Thermodynamic in vitro studies as a method to investigate the pharmacodynamic behavior of adenosine A1 receptor ligands.
Andrea Borea, P; Dalpiaz, A; IJzerman, AP; Pavan, B; Scatturin, A; Varani, K, 1999
)
0.3
" The present study examined the in vitro and in vivo pharmacodynamic profile of the novel and potentially metabolically stable NOP receptor ligand ZP120 (Ac-RYYRWKKKKKKK-NH(2)), which was created by conjugation of a structure-inducing probe (SIP) (i."( Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity.
Kapusta, DR; Kenigs, VA; Meier, E; Petersen, JS; Quist, C; Thorkildsen, C; Vinge, MM, 2005
)
0.33
" Herein, we report the in vitro pharmacological profile and pharmacokinetic properties of another potent, selective, and structurally novel mGlu2/3 receptor agonist, (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3."( Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid
Burkey, JL; Calligaro, DO; Catlow, JT; Giera, DD; Herin, MF; Johnson, BG; Kingston, AE; Marek, GJ; McKinzie, DL; Monn, JA; Nisenbaum, ES; Rorick-Kehn, LM; Schoepp, DD; Wright, RA, 2007
)
0.34
" The method was successfully applied to the pharmacokinetic study after an intravenous administration of isoforskolin in beagle dogs."( A sensitive and specific HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of isoforskolin in beagle dogs.
Chen, J; Huang, J; Ling, Y; Tian, L; Wang, Y; Yin, J, 2011
)
0.37

Compound-Compound Interactions

ExcerptReferenceRelevance
" Here we demonstrate that extracellular ATP, ADP or AMPPNP caused synergistic enhancement of DNA synthesis in 3T6 mouse fibroblasts and BALB/MK keratinocytes when combined with any of the above polypeptides."( Extracellular ATP shows synergistic enhancement of DNA synthesis when combined with agents that are active in wound healing or as neurotransmitters.
Heppel, LA; Huang, NN; Wang, DJ, 1990
)
0.28
"This study demonstrates synergistic effects on Tac expression by interleukin 1 (IL-1) or tumor necrosis factor alpha (TNF alpha) in combination with the adenylate cyclase stimulator, forskolin (FK), as well as by IL-1 with TNF alpha in the human NK-like leukemic cell line YT."( Synergistic induction of interleukin 2 receptor (TAC) expression on YT cells by interleukin 1 or tumor necrosis factor alpha in combination with cAMP inducing agents.
Altman, A; Scholz, W, 1989
)
0.28
" Our findings indicate the involvement of cyclic AMP in the regulation of neurohypophysis as well as the increase in total adenylyl cyclase both after application of immobilization stress combined with water immersion and after chronic amphetamine treatment."( Effects of immobilization stress combined with water immersion and chronic amphetamine treatment on the adenylyl cyclase activity in rat neurohypophysis.
Englisová, D; Hynie, S; Kaminský, O; Klenerová, V; Nazarov, E; Sída, P; Stöhr, J, 1999
)
0.3
"Anticonvulsant effect of cytoskeletal depolymerizing drugs in combination with potassium channel (KATP) opener and adenylate cyclase activator was evaluated in animal models of epilepsy."( Anticonvulsant effect of cytoskeletal depolymerizers in combination with potassium channel opener and adenylate cyclase activator; a causative link with nerve growth factor?
Jose, VM; Tyagi, MG, 2001
)
0.31
"To evaluate which vasoactive agents have synergistic effects on the cavernosal smooth muscles of rabbits and rats when the agents are combined with sildenafil."( Synergistic effects of sildenafil on relaxation of rabbit and rat cavernosal smooth muscles when combined with various vasoactive agents.
Jun, IO; Kim, SC; Lee, MY; Oh, MM; Seo, KK, 2001
)
0.31
" There was significant synergism on rabbit cavernosal smooth muscle when the sildenafil was combined with forskolin, sodium nitroprusside, VIP or phentolamine."( Synergistic effects of sildenafil on relaxation of rabbit and rat cavernosal smooth muscles when combined with various vasoactive agents.
Jun, IO; Kim, SC; Lee, MY; Oh, MM; Seo, KK, 2001
)
0.31
" TBT, when given alone and also in combination with forskolin, decreased IL-1β, TNFα, IFNγ, IFNα, Mx3, and IGF-1 gene expression."( Immune-regulatory transcriptional responses in multiple organs of Atlantic salmon after tributyltin exposure, alone or in combination with forskolin.
Arukwe, A; Pavlikova, N, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" The potential of these alternative formulations for increasing the ocular bioavailability of forskolin is discussed."( Preparation and evaluation in rabbits of topical solutions containing forskolin.
Burgalassi, S; Giannaccini, B; Saettone, MF, 1989
)
0.28
" Expression of IGFBP-1 to -6 by MC suggests that these proteins may modulate IGF-I bioavailability in the glomerulus."( Characterization of insulin-like growth factor binding proteins and regulation of IGFBP3 in human mesangial cells.
Abboud, HE; Abboud, SL; Fouqueray, B; Grellier, P; Sabbah, M; Woodruff, K; Yee, D, 1996
)
0.29
" CRF-binding protein (CRF-BP) regulates the bioavailability of CRF, and knowledge of the regulation of CRF-BP synthesis is an integral component of understanding the actions of CRF."( Coordinate and divergent regulation of corticotropin-releasing factor (CRF) and CRF-binding protein expression in an immortalized amygdalar neuronal cell line.
Balasubramaniam, A; Kasckow, JW; Mulchahey, JJ; Regmi, A; Sheriff, S, 1999
)
0.3
" To examine the hypothesis that altered bioavailability of iodine is a contributing event in the pathogenesis of AIH, we compared the effects of AMD and inorganic iodine in vitro on events involved in the process of thyroid autoregulation."( Amiodarone compared with iodine exhibits a potent and persistent inhibitory effect on TSH-stimulated cAMP production in vitro: a possible mechanism to explain amiodarone-induced hypothyroidism.
Boyages, SC; Pitsiavas, V; Smerdely, P, 1999
)
0.3
" Compound 16 was identified as an orally bioavailable agonist at MT(1) and MT(2) melatonin receptors with low vasoconstrictive activity."( Heterocyclic aminopyrrolidine derivatives as melatoninergic agents.
Chen, J; Deskus, JA; Epperson, JR; Hodges, DB; Iben, L; Li, WS; Luo, G; Mahle, CD; Mattson, RJ; Molstad, D; Ortiz, A; Ryan, E; Sun, LQ; Takaki, K; Xu, C; Yeleswaram, K, 2003
)
0.32
" Transporter-targeted drug delivery has become a clinically significant drug-delivery approach for enhancing the bioavailability of various drugs."( Identification and functional characterization of riboflavin transporter in human-derived retinoblastoma cell line (Y-79): mechanisms of cellular uptake and translocation.
Jain, R; Kansara, V; Mitra, AK; Pal, D, 2005
)
0.33
" From a panel of short chain fatty acid derivatives, we showed that 2,2-dimethyl-butyrate (ST20) and alpha-methylhydrocinnamic acid (ST7), exhibiting high oral bioavailability and sustained plasma levels, correct the DeltaF508-CFTR defect."( Novel short chain fatty acids restore chloride secretion in cystic fibrosis.
Kim, US; Nguyen, TD; Perrine, SP, 2006
)
0.33
" Interestingly, despite the slightly lower potency (approximately 2-5-fold) of LY404039 versus LY354740 in binding, functional, and electrophysiological assays, LY404039 demonstrated higher plasma exposure and better oral bioavailability in pharmacokinetic experiments."( Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid
Burkey, JL; Calligaro, DO; Catlow, JT; Giera, DD; Herin, MF; Johnson, BG; Kingston, AE; Marek, GJ; McKinzie, DL; Monn, JA; Nisenbaum, ES; Rorick-Kehn, LM; Schoepp, DD; Wright, RA, 2007
)
0.34
" The poor bioavailability and therefore poor therapeutic response exhibited by the conventional ophthalmic solutions due to pre-corneal elimination of a drug may be overcome by the use of the in situ gel forming systems, which upon instillation as drops into the eye, undergo a sol-gel transition in the cul-de-sac."( Design and evaluation of thermoreversible in situ gelling system of forskolin for the treatment of glaucoma.
Gupta, S; Samanta, MK,
)
0.13
"The present study was designed to improve the bioavailability of forskolin by the influence of precorneal residence time and dissolution characteristics."( Dual-drug delivery system based on in situ gel-forming nanosuspension of forskolin to enhance antiglaucoma efficacy.
Gupta, S; Raichur, AM; Samanta, MK, 2010
)
0.36
" Based on these observations we propose that increased CCL5 bioavailability could have a role in determining the abovedescribed impaired presynaptic impairments in both CNS regions."( CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice.
Casazza, S; Di Prisco, S; Merega, E; Milanese, M; Pistoia, V; Pittaluga, A; Raffaghello, L; Summa, M; Uccelli, A, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

We investigated pharmacokinetics of colforsin daropate in cardiac surgery patients. We performed simulations to determine the dosage necessary to maintain an effective plasma concentration following cardiopulmonary bypass.

ExcerptRelevanceReference
" Dopamine and the GABAB receptor agonist baclofen both inhibited cyclic-AMP efflux and alpha-MSH release, with similar dynamics of inhibition and similar dose-response relationships."( Dynamics of cyclic-AMP efflux in relation to alpha-MSH secretion from melanotrope cells of Xenopus laevis.
de Koning, HP; Huchedé, B; Jenks, BG; Roubos, EW, 1992
)
0.28
" The dose-response curve for this suppression was very similar to that for stimulation of inositol monophosphate (IP1) formation and for stimulation of the initial rise of [Ca2+]i elicited by carbachol."( Suppressive effect of carbachol on forskolin-stimulated neurite outgrowth in human neuroblastoma NB-OK1 cells.
Nakagawa-Yagi, Y; Nakamura, H; Saito, Y; Takada, Y, 1992
)
0.28
" Preincubation of opossum kidney cell line cell monolayers with 5-HT resulted in 5-HT1B receptor-mediated desensitization expressed as a 4-fold rightward shift of the dose-response curve and a 10 to 29% decrease of maximal inhibition of forskolin-stimulated cyclic AMP production."( Desensitization and down-regulation of the 5-hydroxytryptamine1B receptor in the opossum kidney cell line.
Bylund, DB; Pleus, RC, 1992
)
0.28
" A beta 1-pattern was seen in both regions when lipolysis dose-response curves were arranged in order of potency."( Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells.
Arner, P; Hellmér, J; Marcus, C; Sonnenfeld, T, 1992
)
0.28
" When RFL9-transfected cells were compared with VA 13 fibroblasts, the human cell line in which endogenous A2b-adenosine receptors were originally characterized, the dose-response curves of cAMP responses to drug treatments were highly correlated."( RFL9 encodes an A2b-adenosine receptor.
Reppert, SM; Rivkees, SA, 1992
)
0.28
" Dose-response curves of PMA and of forskolin for the inhibition of PLC-gamma 1 tyrosine phosphorylation and of PtdIns 4,5-P2 hydrolysis were similar."( Inhibition of CD3-linked phospholipase C by phorbol ester and by cAMP is associated with decreased phosphotyrosine and increased phosphoserine contents of PLC-gamma 1.
Min, HK; Park, DJ; Rhee, SG, 1992
)
0.28
" Receptor responses were affected however; the maximum response to N-ethylcarboxamidoadenosine (an A2 receptor agonist) was reduced by 30-40%, there was a small but consistent shift to the right of the dose-response curve for iloprost (a stable analogue of prostacyclin) and [3H]iloprost binding studies revealed a loss of prostacyclin receptors."( Cyclic AMP produces desensitization of prostacyclin and adenosine A2 receptors in hybrid cell lines but does not affect Gs function.
Austin, A; Docherty, K; Keen, M; Kelly, E; Krane, A; MacDermot, J; Taylor, N; Wiltshire, R, 1992
)
0.28
" In the absence of other secretagogues, VIP produced a modest, sustained saliva flow with a biphasic dose-response curve in which saliva volume was greatest at 1 nM VIP (28."( Regulation of secretion by vasoactive intestinal peptide in isolated perfused rat submandibular glands.
Camden, JM; Turner, JT, 1992
)
0.28
" With the portal vein isolated, the parathyroid hormone shifted the dose-response curves of KCl and acetylcholine to the right."( Responsiveness to synthetic parathyroid hormone in the portal vein of portal hypertensive rats.
Chao, TW; Kuo, JS; Pang, PK; Yang, MC; Yu, PC, 1992
)
0.28
" Isoproterenol-stimulated dose-response activation of adenylate cyclase was unchanged between 3 and 12 months but decreased at 24 months (p less than ."( Beta-adrenergic signal transduction in aging parotid and submandibular salivary glands.
Rajakumar, G; Scarpace, PJ, 1991
)
0.28
" For each drug dose-response curves could be constituted in single hippocampal tissues at each of the time points of sacrifice."( Dose-dependent stimulation of adenylate cyclase in rat hippocampal tissue by isoprenaline, Gpp(NH)p and forskolin: lack of circadian phase-dependency.
Carlebach, R; Lemmer, B; Nitsch, R; Ohm, TG; Stiller, M, 1991
)
0.28
" Upon pretreatment with morphine over greater than or equal to 12 h, a fourfold shift of the PGE1-morphine dose-response curve was observed, whether or not IBMX was added."( Regulation of cyclic AMP by the mu-opioid receptor in human neuroblastoma SH-SY5Y cells.
Duan, DS; Eiger, S; Lameh, J; Sadée, W; Yu, VC, 1990
)
0.28
" The dose-response relation with AVP thus shifted to the right."( Inhibition by phorbol ester of cellular adenosine 3',5'-monophosphate production and cellular free calcium mobilization in response to arginine vasopressin in rat renal papillary collecting tubule cells in culture.
Ishikawa, S; Saito, T, 1991
)
0.28
" FSH dose-response studies at 48 h revealed a significant stimulatory effect of 30 ng/ml FSH on P450scc mRNA accumulation and progesterone production, with a maximal effect at 100 ng/ml FSH."( Follicle-stimulating hormone increases concentrations of messenger ribonucleic acid encoding cytochrome P450 cholesterol side-chain cleavage enzyme in primary cultures of porcine granulosa cells.
Garmey, JC; Shupnik, MA; Urban, RJ; Veldhuis, JD, 1991
)
0.28
" Furthermore, Ti/CD3 stimulation did not influence the kinetics or dose-response of GTP[S]-induced inositol phosphate production, suggesting that the Ti/CD3 complex does not regulate guanine nucleotide exchange on the G protein pool stimulated by GTP[S]."( An analysis of the role of guanine nucleotide binding proteins in antigen receptor/CD3 antigen coupling to phospholipase C.
Cantrell, DA; Graves, JD, 1991
)
0.28
" IC50s determined from dose-response curves of inhibition are consistent with the known abilities of these ligands to modulate cyclic AMP and physiological responses in other tissues."( Neuropeptide Y and somatostatin inhibit stimulated cyclic AMP production in rabbit ciliary processes.
Bausher, LP; Horio, B, 1990
)
0.28
" The slope of the dopamine dose-response curve was, however, similar to that of the dose-response curve of clonidine."( Inhibitory effects of clonidine and dopamine on adenylate cyclase of rabbit ciliary processes.
Cepelík, J; Hynie, S, 1990
)
0.28
" The activation of the three cascades induced the expression of the protooncogenes c-fos and c-myc with dose-response curves similar to those for DNA synthesis."( Regulation of protooncogenes c-fos and c-myc expressions by protein tyrosine kinase, protein kinase C, and cyclic AMP mitogenic pathways in dog primary thyrocytes: a positive and negative control by cyclic AMP on c-myc expression.
Dumont, JE; Maenhaut, C; Reuse, S, 1990
)
0.28
" Porcine and human NPY and porcine PYY gave similar dose-response curves."( Characterization of functional neuropeptide Y receptors in a human neuroblastoma cell line.
Fishman, PH; Gordon, EA; Kohout, TA, 1990
)
0.28
" The hCG dose-response curve was shifted to the right by the addition of IL-2."( Interleukin-2 is a potent inhibitor of Leydig cell steroidogenesis.
Calkins, JH; Guo, H; Lin, T; Sigel, MM, 1990
)
0.28
"1-100 mumol/l) were determined from dose-response curves."( Influence of age on the rhythm in basal and forskolin-stimulated adenylate cyclase activity of the rat heart.
Lemmer, B; Wald, C, 1990
)
0.28
" We assessed the possible role of each of these components with age by measuring forskolin dose-response stimulation of adenylate cyclase activity in the presence and absence of guanosine 5'-O-(2-thiodiphosphate) (GDP-beta S) and beta,gamma-imidoguanine 5'-triphosphate (Gpp(NH)p) in myocardial membranes from F-344 rats of 3, 12, and 24 months of age."( Forskolin activation of adenylate cyclase in rat myocardium with age: effects of guanine nucleotide analogs.
Scarpace, PJ, 1990
)
0.28
" Dose-response studies revealed that PGF2 alpha increased the potency of insulin in granulosa cells (EC50 for insulin-stimulation of oxytocin release reduced from 141 to 13 nmol/l by 1 mumol PGF2 alpha/l), but not in luteal cells."( Chronic regulation of ovarian oxytocin and progesterone release by prostaglandins: opposite effects in bovine granulosa and early luteal cells.
McArdle, CA, 1990
)
0.28
" DA was less potent than VIP, and stimulated cyclase activity with a monophasic dose-response curve."( Interactions between vasoactive intestinal peptide and dopamine in the rabbit retina: stimulation of a common adenylate cyclase.
Lam, DM; Pachter, JA, 1986
)
0.27
" A dose-response study showed that FSH pretreatment produced three separate effects on Sertoli cell steroidogenesis: an increased basal production of estrogen; a decreased maximal response when doses of 10 ng/ml FSH or higher were employed in the preincubation; and a decreased sensitivity of the Sertoli cell to FSH."( Effect of phosphodiesterase inhibitors on Sertoli cell refractoriness: reversal of the impaired androgen aromatization.
Conti, M; Geremia, R; Monaco, L; Stefanini, M, 1986
)
0.27
" Both peptides shifted the FSH dose-response curve to the left, making the cells more sensitive to this gonadotropin."( Stimulation of adenosine 3',5'-monophosphate production in rat Sertoli cells by alpha-melanotropin-stimulating hormone (alpha MSH) and des-acetyl alpha MSH.
Bardin, CW; Boitani, C; Mather, JP, 1986
)
0.27
" Analysis of the forskolin dose-response kinetics indicated a dose-dependent increase in the accumulation of cAMP."( Evaluation of the effects of forskolin and the antilipolytic agents insulin and nicotinic acid on cyclic AMP levels in rat epididymal adipocytes.
Fatemi, SH, 1986
)
0.27
" A close dose-response relationship existed for forskolin and for cholera toxin between cAMP generation and carcinoembryonic antigen release."( Effects of cyclic adenosine 3':5'-monophosphate upon glycoprotein and carcinoembryonic antigen synthesis and release by human colon cancer cells.
Hwang, WI; Kim, YS; Sack, TL, 1986
)
0.27
" The dose-response inhibition curve was paralleled by a forskolin-induced increase in cyclic AMP (cAMP) levels in human leukocyte preparations."( Forskolin inhibits the release of histamine from human basophils and mast cells.
Columbo, M; Formisano, S; Marone, G; Triggiani, M; Vigorita, S, 1986
)
0.27
" In preparations precontracted by a higher concentration of KCl, 40 mM, forskolin produced full relaxation with a shift of the dose-response curve to the right; adenosine did not produce full relaxation."( Vasodilation produced by forskolin compared with that produced by adenosine in rabbit coronary artery.
Fujiwara, M; Hama, T; Hisajima, H; Kurahashi, K; Usui, H,
)
0.13
" The dose-response curves for VIP- and PHI-stimulated cAMP accumulation were superimposable on those for PRL secretion."( Vasoactive intestinal peptide and peptide with N-terminal histidine and C-terminal isoleucine increase prolactin secretion in cultured rat pituitary cells (GH4C1) via a cAMP-dependent mechanism which involves transient elevation of intracellular Ca2+.
Bjøro, T; Gautvik, KM; Gordeladze, J; Haug, E; Iversen, JG; Ostberg, BC; Sand, O; Torjesen, PA, 1987
)
0.27
"On isolated electrically stimulated left and spontaneously beating right guinea-pig atria the interaction between PDE-inhibitors and the positive inotropic and chronotropic action of orciprenaline, forskolin and histamine in dose-response curve was examined."( Interaction of phosphodiesterase inhibitors triamterene, papaverine, theophylline, IBMX and amrinone with other positive inotropic acting substances on isolated guinea-pig atria.
Greeff, K; Schmitt, M, 1987
)
0.27
" Addition of 10(-8) M SP caused a shift to the left in the secretion dose-response curve caused by ISO, but did not enhance ISO-induced maximal response."( [3H]protein secretion in rat parotid gland: substance P-beta-adrenergic synergism.
Dreux, C; Imhoff, V; Rossignol, B, 1987
)
0.27
" Synergistic responses were observed with combinations of any two of the three secretagogues such that subthreshold doses of one caused a pronounced shift in the dose-response curve to the second."( Synergistic interactions between forskolin, isoprenaline and substance P as secretagogues in rat parotid glands.
Cowburn, R; Cripps, HE; Iversen, LL; Poat, JA, 1987
)
0.27
" First, when the dose-response curve of PTH-induced ODC activity is compared with that of PTH-stimulated cAMP production, the ED50 for cAMP production is about five times as high as that for the induction of ODC activity."( Induction of ornithine decarboxylase activity in isolated chicken osteoblasts by parathyroid hormone: the role of cAMP and calcium.
Herrmann-Erlee, MP; Löwik, CW; Olthof, AA; van Leeuwen, JP; van Zeeland, JK, 1988
)
0.27
" The dose-response curves of the strips from both strains for alpha-adrenoceptor stimulation with NA determined after pretreatment with CTX were comparable to those determined in the absence of timolol."( Role of stimulatory GTP-binding protein (Gs) in reduced beta-adrenoceptor coupling in the femoral artery of spontaneously hypertensive rats.
Asano, M; Masuzawa, K; Matsuda, T, 1988
)
0.27
" Moreover, PDBu, which causes attenuation of the maximal response to vasoactive intestinal polypeptide (VIP), also induced a small right shift in the dose-response curve for VIP-induced cyclic AMP accumulation."( Regulation of GH3 pituitary tumour-cell adenylate cyclase activity by activators of protein kinase C.
Brown, BL; Dobson, PR; Quilliam, LA, 1989
)
0.28
" Forskolin administered at a dosage of 4 micrograms/kg/min induced an increase in dP/dtmax by 19% and a 16% rise in heart rate."( Cardiovascular effects of forskolin and phosphodiesterase-III inhibitors.
Mitrovic, V; Schlepper, M; Thormann, J, 1989
)
0.28
" Forskolin, cholera toxin and dibutyryl cyclic AMP also affected C6 cell proliferation, and the dose-response for decreasing the receptor was very similar to that observed for the inhibition of cell growth, suggesting a relationship between both phenomena."( Effects of cyclic AMP elevation on the levels of insulin receptors in glial C6 cells.
Aranda, A; Montiel, F; Pascual, A, 1989
)
0.28
" The epinephrine dose-response curve in the presence of 10(-8) M met-enkephalin was similar to that of epinephrine alone."( Combinative ligand-receptor interactions: effects of cAMP, epinephrine, and met-enkephalin on RAW264 macrophage morphology, spreading, adherence, and microfilaments.
Martin, SM; Petty, HR, 1989
)
0.28
" In the presence of PTH, the response to forskolin was potentiated over the whole dose-response curve with apparent EC50 value at 1-2 mumol/l of forskolin."( Forskolin sensitizes parathyroid hormone-induced cyclic AMP response, but not the bone resorptive effect, in mouse calvarial bones.
Fredholm, BB; Lerner, UH; Ljunggren, O; Ransjö, M; Sahlberg, K, 1989
)
0.28
"16E cells with a dose-response curve (ED50, 4 nM) very similar to that observed for the modulation of mucin secretion."( Functional VIP receptors in the human mucus-secreting colonic epithelial cell line CL.16E.
Augeron, C; Grasset, E; Laboisse, C; Laburthe, M; Maoret, JJ; Roumagnac, I; Rouyer-Fessard, C, 1989
)
0.28
" Dose-response studies revealed a dose-dependent increase in beta-adrenergic receptor-stimulated cAMP production."( Glucocorticoid administration increases receptor-mediated and forskolin-stimulated cyclic AMP accumulation in rat brain cerebral cortical slices.
Duman, RS; Enna, SJ; Strada, SJ, 1989
)
0.28
" Dose-response studies were consistent with insulin acting via receptors for IGF-I, and IGF-I caused a similar effect."( Insulin-like growth factor-I potentiates thyrotropin stimulation of adenylyl cyclase in FRTL-5 cells.
Berg, KA; Brenner-Gati, L; Gershengorn, MC, 1989
)
0.28
" In slices from methamphetamine-treated rats, the dose-response curve for the dopamine hyperpolarization was shifted to the left of that seen in neurones from control rats by a factor of approximately 100."( Enhancement of dopamine actions on rat nucleus accumbens neurones in vitro after methamphetamine pre-treatment.
Higashi, H; Inanaga, K; Nishi, S; Uchimura, N, 1989
)
0.28
" However, in class III, there was a significant shift to the right of the dose-response curves to nitroglycerin and SIN1 (but not to forskolin)."( Alterations of beta-adrenoceptor mediated relaxations of atherosclerotic human coronary arteries.
Berkenboom, G; Degre, S; Fontaine, J, 1989
)
0.28
" Thus (-)-baclofen (100 microM) shifted the dose-response curve to forskolin to the right 5 fold in an apparently parallel fashion."( GABAB receptor modulation of adenylate cyclase activity in rat brain slices.
Hill, DR, 1985
)
0.27
"When the dose-response curve of adrenocorticotropin (ACTH)-induced aldosterone secretion is compared to that of ACTH-induced intracellular cAMP, the ED50 for intracellular cAMP is more than 10 times as high as that for aldosterone production."( Role of calcium and cAMP in the action of adrenocorticotropin on aldosterone secretion.
Kojima, I; Kojima, K; Rasmussen, H, 1985
)
0.27
" Dose-response curves showed a significantly greater stimulation of adenylate cyclase activity in the positive group at forskolin concentrations of 10(-7) to 2 x 10(-4) mol/l."( Increased forskolin stimulation of lymphocyte-adenylate cyclase in normotensive subjects predisposed to essential hypertension.
Distler, A; Fritschka, E; Pauliks, LB; Philipp, T; Schultz, KD, 1989
)
0.28
" Co-incubation of cells with 1 microM A23187 caused parallel upward shift of the TPA dose-response curve, and the further addition of 10 microM forskolin led to further upward shift."( Mechanisms of TSH release: studies with forskolin, phorbol ester and A23187.
Davis, JR; Sheppard, MC, 1987
)
0.27
" The 1-MeAde dose-response curves for maturation induction and activation of the histone H1 and RRLSSLRA kinases were superimposable."( Differential regulation of histone H1 and ribosomal S6 kinases during sea star oocyte maturation.
Krebs, EG; Meijer, L; Pelech, SL, 1987
)
0.27
" alpha 2-Adrenergic agonist preincubation also resulted in desensitization as indicated by a shift to the right in the dose-response curve of a subsequent challenge by an alpha 2-adrenergic agonist."( Characterization and possible mechanisms of alpha 2-adrenergic receptor-mediated sensitization of forskolin-stimulated cyclic AMP production in HT29 cells.
Bylund, DB; Jones, SB, 1988
)
0.27
" Dose-response curves to isoproterenol were determined in the presence and absence of adenosine deaminase."( Quantitative differences in the cyclic AMP-lipolysis relationships for isoproterenol and forskolin.
Allen, DO; Quesenberry, JT, 1988
)
0.27
" The NTLI response to epinephrine was competitively inhibited by propranolol, producing a parallel rightward shift of the epinephrine dose-response curve."( Regulation of neurotensin release from canine enteric primary cell cultures.
Barber, DL; Buchan, AM; Soll, AH; Walsh, JH, 1986
)
0.27
" The dose-response curve for stimulation by histamine of adenylate cyclase was shifted to the right in a dose-dependent manner by increasing concentrations of several H2-antagonists."( A study of the H2-receptor for histamine stimulating adenylate cyclase in homogenates of guinea-pig lung parenchyma.
Foreman, JC; Norris, DB; Rising, TJ; Webber, SE, 1986
)
0.27
" The muscarinic antagonist atropine, 1 microM, and the beta 2-adrenoceptor antagonist propranolol, 10 microM, had no effect on the dose-response curve for dimaprit-induced relaxation of the lung strip."( A study of the histamine H2-receptor mediating relaxation of the parenchymal lung strip preparation of the guinea-pig.
Foreman, JC; Rising, TJ; Webber, SE, 1985
)
0.27
" A dose-response relationship between inhibition of alpha-MSH secretion and the concentration of Leu-enkephalin, with ED50 approximately 10(-9) M, was observed."( Modulation by Leu-enkephalin of peptide release from perifused neurointermediate pituitary. II. Inhibition of calcium-mediated secretion of alpha-MSH and beta-endorphin.
Al Zein, M; Koch, B; Lutz-Bucher, B, 1986
)
0.27
" The dose-response curve to forskolin was bell-shaped (as is seen with TSH and LATS-B) with the ascending limb of the curve produced by 10(-13) M to 10(-12) M forskolin after a 3 min exposure time."( Forskolin stimulation of naphthylamidase in guinea pig thyroid sections detected with a cytochemical bioassay.
Ealey, PA; Ekins, RP; Kohn, LD; Marshall, NJ, 1985
)
0.27
"1 microM SCH 23390, a selective D1 antagonist, the DA dose-response curve was shifted rightward in a competitive manner."( D2-dopamine receptor-mediated inhibition of cyclic AMP formation in striatal neurons in primary culture.
Bockaert, J; Garcia-Sainz, JA; Sebben, M; Weiss, S, 1985
)
0.27
" Interestingly, in the absence of 1-methyl-3-isobutylxanthine (or an adenosine blocker), or in the presence of 1-methyl-3-isobutylxanthine (2 mM) and forskolin (30 microM), prostaglandin E1 (1 nM-100 microM) exhibited biphasic dose-response kinetics."( Interaction between prostaglandin E1 and forskolin in modulation of cyclic AMP levels in rat epididymal adipocytes.
Fatemi, SH, 1985
)
0.27
" In contrast, PGD2 acted as a weak and partial inhibitor in guinea-pig platelet aggregation, producing a bell-shaped dose-response relationship."( Interaction of prostaglandin D2 with prostacyclin, carbacyclin and the hydantoin prostaglandin, BW245C, in guinea-pig platelets.
Hamid, S; Whittle, BJ, 1985
)
0.27
" The forskolin dose-response curve was not altered by theophylline, but was shifted to the left by approximately 10-fold with dipyridamole and ZK 62 711 and 5-fold with IBMX."( Forskolin, phosphodiesterase inhibitors, and cyclic AMP analogs inhibit proliferation of cultured bovine aortic endothelial cells.
Fiscus, RR; Leitman, DC; Murad, F, 1986
)
0.27
" The dose-response to ACTH was similar for cyclic AMP and corticosterone but aldosterone secretion appeared to be more sensitive to ACTH stimulation."( Relationship between endogenous cyclic AMP production and steroid hormone secretion in chick adrenal cells.
Hurwitz, S; Pines, M; Rosenberg, J, 1986
)
0.27
" Pretreatment of cells with forskolin led to a parallel upward shift in the subsequent TRH dose-response curve, without a significant change in median effective dose or any change in cellular TSH content."( A modulatory role for cyclic AMP in the control of thyrotrophin release: studies with forskolin and dibutyryl cyclic AMP.
Davis, JR; Sheppard, MC, 1986
)
0.27
" In contrast, dose-response curves for GTP-stimulation of basal and isoproterenol-stimulated adenylate cyclase display higher maximal responses in fasted rats under conditions restraining (2 mM Mg2+) but not promoting (10 mM Mg2+) the dissociation of Ns."( Fasting increases fat cell adenylate cyclase sensitivity to stimulatory agonists through enhanced ability of the stimulatory regulatory component Ns to dissociate.
Agli, B; Giudicelli, Y; Lacasa, D, 1986
)
0.27
" In studies with isolated rat hearts perfused in the Langendorff mode, the dose-response characteristics of forskolin have been characterized."( Forskolin and myocardial function in the normal, ischemic and reperfused rat heart.
Buschmans, E; Hearse, DJ; Manning, AS; Zucchi, R,
)
0.13
" Insulin secretory dose-response curves utilizing static incubations fit a single binding site model and established that glyburide (ED50 = 112 +/- 18 nM) is a more potent secretagogue than tolbutamide (ED50 = 15 +/- 3 microM)."( Increased cytosolic calcium. A signal for sulfonylurea-stimulated insulin release from beta cells.
Berg, M; Boyd, AE; Gaines, KL; Nelson, TY; Rajan, AS, 1987
)
0.27
"1 mM) there was a dose-response effect and SQ20,006 was more inhibitory."( The effects of forskolin, cAMP, and cyanoketone on steroid-induced meiotic maturation of yellow perch (Perca flavescens) oocytes in vitro.
DeManno, DA; Goetz, FW, 1987
)
0.27
" p[NH]ppG increased forskolin sensitivity and caused a leftward shift in the forskolin dose-response curve."( Forskolin refractoriness. Exposure to the diterpene alters guanine nucleotide-dependent adenylate cyclase and calcium-uptake activity of cells cultured from the rat aorta.
Jamgotchian, N; Krall, JF, 1987
)
0.27
" The vasopressin analogs [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-(O-methyl)tyrosine,8-arginine]vasopressin (SK&F 100273), [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-(O-methyl)tyrosine,4-valine,8-arginine]vasopressin (SK&F 100501), [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-D-tyrosine,4-valine,8-arginine]vasopressin (SK&F 100885), [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-(O-ethyl)tyrosine,4-valine,8-arginine]vasopressin (SK&F 100398), [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-D-isoleucine,4-valine,8-arginine]vasopressin (SK&F 101485), [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-(O-ethyl)-tyrosine,4-valine,8-arginine]vasopressin (SK&F 101498), [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-(O-ethyl)D-tyrosine,4-valine,8-arginine,9-desglycine]vasop ressin (SK&F 101926) and [1-(beta-mercapto-beta-beta-cyclopentamethylene propionic acid),2-D-phenylalanine,4-valine,8-arginine] vasopressin (SK&F 101071) antagonized arginine vasopressin-stimulated water flux and displaced the agonist dose-response relationship to the right in a parallel fashion."( Mechanism of action and structural requirements of vasopressin analog inhibition of transepithelial water flux in toad urinary bladder.
Huffman, W; Kinter, LB; Mann, WA; Stassen, F, 1986
)
0.27
"8 microM) was repeatedly dosed with acetylcholine (ACh, 10 microM)."( The relaxant and spasmogenic effects of some xanthine derivatives acting on guinea-pig isolated trachealis muscle.
Boyle, JP; Cortijo, J; Curtis-Prior, PB; Davies, JM; Foster, RW; Hofer, P; Small, RC, 1988
)
0.27
" The pattern of the TSH dose-response curves suggested that desensitization by TSH or TSAb involved only a postreceptor mechanism but both receptor and postreceptor phenomena in the case of TBkAb."( Blocking anti-thyrotropin receptor antibodies desensitize cultured human thyroid cells.
Clavel, S; Madec, AM; Orgiazzi, J; Stefanutti, A, 1988
)
0.27
" Similar temporal and dose-response relationships were observed for LH-stimulated IP3 and cAMP accumulation."( Luteinizing hormone increases inositol trisphosphate and cytosolic free Ca2+ in isolated bovine luteal cells.
Davis, JS; Farese, RV; Weakland, LL; West, LA, 1987
)
0.27
" Dypiridamole, which in PRP has very little effect on the dose-response curve for ajoene, when assayed in whole blood decreases the ID50 for ajoene by a factor of four."( Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets.
Apitz-Castro, R; Escalante, J; Jain, MK; Vargas, R, 1986
)
0.27
" Mg2+ dose-response curves also reinforced the differences in the Ca2+/CaM requirement for Gpp(NH)p- and morphine-induced inhibition."( Ca2+/calmodulin distinguishes between guanyl-5'-yl-imidodiphosphate- and opiate-mediated inhibition of rat striatal adenylate cyclase.
Ahlijanian, MK; Cooper, DM; Halford, MK, 1987
)
0.27
" The dose-response curve for the action of forskolin (2."( The effect of forskolin on the isometric contraction of the isolated hemidiaphragm of the rat.
Prostran, M; Varagić, VM, 1986
)
0.27
" These conditions have been used to generate forskolin dose-response curves of AC activation."( Forms of adenylate cyclase, activation and/or potentiation by forskolin.
Ho, RJ; Ruiz, JA; Shi, QH, 1986
)
0.27
" Both contractile cholinergic responses and relaxant nonadrenergic noncholinergic dose-response data were obtained for the in vitro bronchial specimens by electrical field stimulation."( Airway reactivity in chronic obstructive pulmonary disease. Failure of in vivo methacholine responsiveness to correlate with cholinergic, adrenergic, or nonadrenergic responses in vitro.
Armour, CL; Hogg, JC; Paré, PD; Schellenberg, RR; Taylor, SM, 1985
)
0.27
" The ED50 for TRH stimulation of hormone release was increased 2- to 4-fold in down-regulated cells, but the dose-response curves for other secretagogues were not shifted."( Differential effects of thyrotropin-releasing hormone, vasoactive intestinal peptide, phorbol ester, and depolarization in GH4C1 rat pituitary cells.
Aizawa, T; Hinkle, PM, 1985
)
0.27
" 5) Pretreatment of membranes with cholera toxin facilitated cyclase activation proportionately more in ob/ob than in +/+ membranes; in addition, this treatment led to a shift to the left of the GTP dose-response curve in the ob/ob membranes."( Absence of the inhibitory effect of guanine nucleotides on adenylate cyclase activity in white adipocyte membranes of the ob/ob mouse. Effect of the ob gene.
Bégin-Heick, N, 1985
)
0.27
" Further analysis of the effects of low mol wt fraction on hCG stimulation of adenylyl cyclase indicated that enzyme inhibition was not accompanied by a shift in the hCG concentration required for half-maximal stimulation (the apparent activation constant) compared to dose-response curves obtained in the absence of added fraction."( Inhibition of luteinizing hormone/human chorionic gonadotropin-stimulable adenylyl cyclase activity in rat luteal membranes by nonsteroidal component(s) in human follicular fluid.
Asch, RH; Cammack, JT; Ellsworth, LR; Rojas, FJ; Ruetzel, C, 1986
)
0.27
" However, the dose-response curve for the GppNHp-dependent increase in [3H]forskolin binding sites is shifted to lower concentrations in the presence of prostaglandin E1."( Regulation of [3H]forskolin binding to human platelet membranes by GppNHp, NaF, and prostaglandin E1.
Nelson, CA; Seamon, KB, 1985
)
0.27
" A dose-response relationship to TSH was obtained 47 h after addition of the hormone."( Thyrotrophin stimulation of mitogenesis of the rat thyroid cell strain FRTL-5: a metaphase index assay for the detection of thyroid growth stimulators.
Bidey, SP; Ealey, PA; Emmerson, JM; Marshall, NJ, 1985
)
0.27
" The dose-response curve to VIP was bell-shaped (as with the other stimulators), maximal stimulation occurring at 10(-12) M VIP."( VIP stimulation of beta-naphthylamidase activity in guinea-pig thyroid sections.
Ealey, PA; Ekins, RP; Marshall, NJ, 1985
)
0.27
" Furthermore, pre-incubation of slices with the direct-acting adenylate cyclase stimulant forskolin shifted the dose-response curves for both phases of NE-induced potentiation to the left."( Blockade of norepinephrine-induced long-lasting potentiation in the hippocampal dentate gyrus by an inhibitor of protein synthesis.
Sarvey, JM; Stanton, PK, 1985
)
0.27
" A biphasic log dose-response curve was observed for each of the cannabinoid drugs, such that reversal of the inhibition occurred at 3-10 microM."( Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes.
Fleming, RM; Howlett, AC, 1984
)
0.27
" Dose-response curves were constructed for the inhibitory action of these agents on both cellular parameters and their interrelationship examined by regression analysis."( Effect of cyclic AMP on cellular contractility and DNA synthesis in chorioretinal fibroblasts maintained in collagen matrices.
Constable, IJ; Martin, CE; van Bockxmeer, FM, 1984
)
0.27
" Alpha-2 adrenergic activation, achieved with 10 muM epinephrine and 30 muM propranolol, significantly inhibited forskolin-stimulated cyclic AMP accumulation and glycerol release, shifting the dose-response curves to the right."( Alpha-2 adrenergic activation inhibits forskolin-stimulated adenylate cyclase activity and lipolysis in human adipocytes.
Burns, TW; Bylund, DB; Forte, LR; Langley, PE; Terry, BE, 1982
)
0.26
" Steady state dose-response curves were obtained for forskolin and 8-bromo-cGMP in the presence of basal myosin phosphorylation."( Myosin phosphorylation and cyclic adenosine 3',5'-monophosphate in relaxation of arterial smooth muscle by vasodilators.
Gerthoffer, WT; Murphy, RA; Trevethick, MA, 1984
)
0.27
" Stimulation of cAMP production in human parathyroid adenomas occurred as early as 2 min and continued for at least 2 h; furthermore, a dose-response relationship was observed, with a maximal 80-fold cAMP response occurring at 100 microM forskolin."( Divergent effects of forskolin on 3',5' cyclic adenosine monophosphate production and parathyroid hormone secretion.
Cantley, LK; Cooper, CW; Leight, GS; Mahaffee, DD; Ontjes, DA; Scott, DL; Thomas, CG, 1984
)
0.27
"5 microM) had no significant effect on relaxation dose-response curves (DRCs) to ACh, NTG or NO."( Role of calcium-activated K+ channels in vasodilation induced by nitroglycerine, acetylcholine and nitric oxide.
Khan, SA; Mathews, WR; Meisheri, KD, 1993
)
0.29
" The dose-response curves of induction of HGF secretion by cholera toxin and forskolin were nearly parallel with those of the intracellular cAMP levels."( Expression of hepatocyte growth factor is up-regulated through activation of a cAMP-mediated pathway.
Gohda, E; Iwao, M; Kataoka, H; Matsunaga, T; Takebe, T; Wu, YL; Yamamoto, I, 1994
)
0.29
" Caffeine shifted the dose-response curves of the [Ca2+]i rise induced by vasopressin (0."( Caffeine inhibits cytosolic calcium oscillations induced by noradrenaline and vasopressin in rat hepatocytes.
Berthon, B; Claret, M; Combettes, L, 1994
)
0.29
" Dose-response and structure-activity relationships were consistent with a process mediated by interaction of TCDD with the Ah receptor."( Inhibition of 3T3-L1 adipose differentiation by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Enan, E; Liu, PC; Matsumura, F; Phillips, M, 1995
)
0.29
" Naloxone also caused a rightward shift of the dose-response curve for dynorphin A, suggesting a competitive antagonism mechanism."( Identification of dynorphins as endogenous ligands for an opioid receptor-like orphan receptor.
Yu, L; Zhang, S, 1995
)
0.29
" The dose-response curve for forskolin was shifted to the right in hypothyroid animals fed the n-3 diet indicating a decrease in sensitivity."( Thyroid status and dietary fatty acids affect beta-adrenoceptor agonist stimulation of tension development in rat myocardium.
Awumey, EM; Paton, DM; Pehowich, DJ, 1995
)
0.29
" Dose-response curves for the inhibition of ROS phagocytosis by forskolin and isoproterenol demonstrated that this process is exquisitely sensitive to these agonists, with an IC50 for these drugs of 33 nmol/l."( The phagocytosis of rod outer segments is inhibited by drugs linked to cyclic adenosine monophosphate production.
Abrams, TA; Hall, MO; Mittag, TW, 1993
)
0.29
" Elevation of intracellular levels of cAMP by forskolin does not result in a significant shift in the IGF/FGF dose-response curves."( Fibroblast growth factors and insulin growth factors combine to promote survival of rat Schwann cell precursors without induction of DNA synthesis.
Brennan, A; Gavrilovic, J; Jessen, KR; Mirsky, R, 1995
)
0.29
" The five opioid peptides induced no changes in the dose-response curves with isoproterenol and forskolin."( Effects of opioid substances on cAMP response to the beta-adrenergic agonist isoproterenol in human mononuclear leukocytes.
Ioverno, A; Lotti, G; Musso, NR; Pende, A; Vergassola, C, 1995
)
0.29
" The model applied for the analysis may be thought to be the best means for the moment to relate dose-response dependencies with what is known or can be hypothesized about the mechanisms underlying activation of adenylate cyclase."( Analysis of effects of corticotropin, forskolin and fluoride on activity of adenylate cyclase of bovine adrenal cortex.
de Foresta, B; Juska, A, 1995
)
0.29
" The dose-response curve of adenylate cyclase to the GTP analogue, GppNHp, was modified by 5HT, which promotes a significantly higher maximal response without altering the potency of GppNHp."( Heterologous sensitization of adenylate cyclase activity by serotonin in the rat cerebral cortex.
Brunello, N; Perez, J; Racagni, G; Rovescalli, AC; Steardo, L; Vitali, S, 1993
)
0.29
" In the presence of 200 microM Rp-cAMPS, the dose-response curves of the dopamine D1 receptor agonists SKF 38393 and fenoldopam were shifted to the left and maximal agonist responses were markedly increased."( Inhibition of dopamine agonist-induced phosphoinositide hydrolysis by concomitant stimulation of cyclic AMP formation in brain slices.
Friedman, E; Undie, AS, 1994
)
0.29
" Many of these ligands give biphasic dose-response curves which suggests that there may be two melatonin receptor subtypes within the ovine pars tuberalis cells."( Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands.
Caignard, DH; Delagrange, P; Depreux, P; Guardiola, B; Howell, HE; Lesieur, D; Mansour, HA; Morgan, P; Pfeiffer, B; Renard, P, 1994
)
0.29
" In the beta cell of aged rats, the following abnormalities were found: (a) right shift of the dose-response curve (depressed sensitivity) of glucose-induced insulin release, (b) no increase of the maximum response to glucose in the face of increased insulin content of the islets (reduced responsiveness), (c) no response to forskolin and normal response to the phorbol ester and glyburide, and (d) increased sensitivity to nifedipine."( Insulin secretion by the pancreatic beta cell of aged rats.
Aizawa, T; Hashizume, K; Ishihara, F; Komatsu, M; Nishii, N; Sato, Y; Suzuki, N; Yamada, T, 1994
)
0.29
" The dose-response curve for glutamate was steep, with a maximal stimulation of 24."( Calcium and cAMP mediated stimulation of Fos in cultured hypothalamic tyrosine hydroxylase-immunoreactive neurons.
Morris, M; Selley, DE; Sim, LJ; Tsai, KP, 1994
)
0.29
" Dose-response relationships of ISO or rolipram show a close correlation of the half-maximal effective dose (ED50) for injury reversal and perfusate cAMP production."( Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor.
Barnard, JW; Prasad, VR; Seibert, AF; Smart, DA; Strada, SJ; Taylor, AE; Thompson, WJ, 1994
)
0.29
" EEDQ treatment shifted the dose-response curve for 5-HT to the right by 6-7-fold, accompanied by a reduction (30-50%) in maximal response."( Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system.
Adham, N; Branchek, T; Ellerbrock, B; Hartig, P; Weinshank, RL, 1993
)
0.29
" Cimetidine decreased IK in the presence of histamine, by shifting the dose-response curve to histamine to the right."( Modulation by histamine of the delayed outward potassium current in guinea-pig ventricular myocytes.
Abiko, Y; Yazawa, K, 1993
)
0.29
" ATP as well as forskolin prevented the adenylyl cyclase inactivation in a dose-response manner independent of the utilized type of cell membranes."( Activated Gs alpha but not Gi alpha prevents the thermal inactivation of adenylyl cyclase in plasma membranes derived from S49 lymphoma cells.
Kvapil, P; Novotny, J; Ransnäs, LA, 1994
)
0.29
" Stimulation of DNA synthesis and inhibition of cAMP accumulation by LPA were inhibited by pertussis toxin, but with different dose-response characteristics."( A novel synergistic stimulation of Swiss 3T3 cells by extracellular ATP and mitogens with opposite effects on cAMP levels.
Heller, EJ; Heppel, LA; Huang, NN; Wang, DJ, 1994
)
0.29
" In addition, the p[NH]ppG dose-response curve of the forskolin-stimulated enzyme was biphasic, similar to that observed for other systems."( Characterization of adenylyl cyclase in goldfish brain.
Henley, JM; Kirkham, DM, 1993
)
0.29
"01-1 microM, A2 selective) shifted the dose-response curve of adenosine in parallel to the right, but they shifted that of cAMP to the right and downwards."( Pharmacological analysis of vasodilation induced by extracellular adenosine 3',5'-cyclic monophosphate in the isolated and perfused canine coronary artery.
Chiba, S; Nakane, T, 1993
)
0.29
" In contrast, exposure of the EP3 beta isoform to PGE2 did not affect its dose-response curve for PGE2, and no sequestration or decrease in the receptor number was observed in this isoform."( Two isoforms of prostaglandin E receptor EP3 subtype. Different COOH-terminal domains determine sensitivity to agonist-induced desensitization.
Ichikawa, A; Irie, A; Narumiya, S; Negishi, M; Sugimoto, Y, 1993
)
0.29
" While the nonmetabolizable adenosine analogue N6-(phenylisopropyl)adenosine (PIA) inhibited ADA-stimulated lipolysis, EGF affected neither ADA-stimulated lipolysis nor the dose-response curve for PIA."( Epidermal growth factor modulates the lipolytic action of catecholamines in rat adipocytes. Involvement of a Gi protein.
Ramírez, I; Soley, M; Tebar, F, 1993
)
0.29
"The major adenylyl cyclase activity (AC) of rabbit ocular ciliary processes was investigated by dose-response analysis with respect to interactions of its regulators [the stimulatory G-protein (alpha S) and forskolin] under both saturating and suboptimal divalent cation (M2+) conditions."( Interactions between forskolin, GS, and divalent cations on ciliary process adenylyl cyclase and intraocular pressure in the rabbit eye.
Mittag, TW; Tormay, A, 1993
)
0.29
" The dose-response curve for melatonin shows an approximate 1000-fold shift in potency in the RCS rat."( Agonist-induced effects on cyclic AMP metabolism are affected in pigment epithelial cells of the Royal College of Surgeons rat.
Nash, MS; Osborne, NN, 1995
)
0.29
" Dose-response curves for the local and distant effects of ISO and FSK on ICa were used as an index of cAMP concentration changes near the sarcolemma."( cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists.
Fischmeister, R; Jurevicius, J, 1996
)
0.29
" The dose-response relationship for isoprenaline and the Cl- current activation was shifted to higher doses in the presence of phenylephrine (30 microM)."( alpha-Adrenergic inhibition of the beta-adrenoceptor-dependent chloride current in guinea-pig ventricular myocytes.
Ehara, T; Hirahara, K; Iyadomi, I, 1995
)
0.29
" Each antagonist alone caused smaller shifts to the right in the dose-response curve to NE and, when present simultaneously, completely abolished the NE response."( Inducible expression of beta 1- and beta 2-adrenergic receptors in rat C6 glioma cells: functional interactions between closely related subtypes.
Esbenshade, TA; Guerrero, SW; Minneman, KP; Zhong, H, 1996
)
0.29
" A dose-response curve for 1,9-dideoxyforskolin gave an estimated IC50 of 54 microM."( Forskolin's structural analogue 1,9-dideoxyforskolin has Ca2+ channel blocker-like action in rat cerebellar granule cells.
Becherer, U; Feltz, A; Rodeau, JL; Zerr, P, 1996
)
0.29
" In support of this postulate, we compared the responses obtained with platelets with those of cloned EP4 (stimulatory) and EP3 (inhibitory) prostaglandin receptor subtypes and show similar dose-response curves for stimulation and inhibition of cyclic AMP formation between platelets and cloned receptors."( Prostaglandin E2 both stimulates and inhibits adenyl cyclase on platelets: comparison of effects on cloned EP4 and EP3 prostaglandin receptor subtypes.
Ashby, B; Bastepe, M; Jin, JG; Mao, GF; Ortiz-Vega, S, 1996
)
0.29
" The PKA-activator forskolin mimicked the effect of dopamine and enhanced glutamate-induced currents, while application of the PKC stimulator PMA or the synthetic diacylglycerol analogue OAG had no significant effects on the dose-response curves of glutamate induced-currents."( Protein kinase C does not mediate the dopamine-dependent modulation of glutamate receptors in retinal horizontal cells of the perch (Perca fluviatilis).
Schmidt, KF, 1996
)
0.29
" Increasing the concentration of insulin during the incubation allowed construction of dose-response curves of insulin inhibition of lipolysis."( Antilipolytic effect of insulin and insulin receptor messenger RNA expression in adipocytes of infants, children, and adults.
Ehrén, H; Hildingsson, U; Kamel, A; Marcus, C; Norgren, S, 1997
)
0.3
" The results were as follows: H-89 interfered with forskolin or IBMX arrested oocytes in dose-response manner (IBMX ED50 = 41 microM for COCs; forskolin ED50 = 9 microM for denuded oocytes)."( Roles of protein kinase A and C in spontaneous maturation and in forskolin or 3-isobutyl-1-methylxanthine maintained meiotic arrest of bovine oocytes.
Bavister, BD; Rose-Hellekant, TA, 1996
)
0.29
" The first goal of the study was to investigate the role of melatonin on myocardial contractility in isolated rat papillary muscle using dose-response curves to melatonin, to isoproterenol and calcium either in the presence or in the absence of melatonin (0."( Effects of melatonin in isolated rat papillary muscle.
Abete, P; Bianco, S; Cacciatore, F; Calabrese, C; Ferrara, N; Napoli, C; Rengo, F, 1997
)
0.3
" Dose-response curves to the hormone were determined in the absence and in the presence of several drugs that affect sequential steps of the Ca(2+)-dependent signalling pathway."( Cellular signalling of PCH-induced pigment aggregation in the crustacean Macrobrachium potiuna erythrophores.
Castrucci, AM; da Silva, MA; Josefsson, L; Nery, LE, 1997
)
0.3
" A concurrent drop in Rt was noted at all TDCA concentrations, the duration of which correlated with dosage and degree of histological damage."( Acute effects of bile acids on the pancreatic duct epithelium in vitro.
Alvarez, C; Bass, BL; Fasano, A, 1998
)
0.3
" Dose-response curves for isoprenaline-induced force of contraction showed unchanged maximum effects but significantly increased pD2 values."( Functional coupling of overexpressed beta 1-adrenoceptors in the myocardium of transgenic mice.
Böhm, M; Flesch, M; Kilter, H; Mansier, P; Schnabel, P; Swynghedauw, B; Zolk, O, 1998
)
0.3
" Dose-response curves for stimulation of both promoter constructs by PROG were biphasic."( Progesterone stimulates the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells.
Baulieu, EE; Brown, AM; Désarnaud, F; Do Thi, AN; Lemke, G; Schumacher, M; Suter, U, 1998
)
0.3
" We used primary cerebrocortical cell cultures from fetal mice to examine the dose-response and time-course of ppSom gene expression in response to the cyclic-AMP analogs, dibutyrl-cAMP (dbcAMP), and 8-bromo-cAMP (8-BrcAMP)."( Regulation of the preprosomatostatin gene by cyclic-AMP in cerebrocortical neurons.
Capone, G; Choi, C; Vertifuille, J, 1998
)
0.3
" The (+)8-OH-DPAT dose-response curve was completely reversed by 5-HT1A receptor antagonists in rat cortex and all human brain areas."( Effects of postmortem delay on serotonin and (+)8-OH-DPAT-mediated inhibition of adenylyl cyclase activity in rat and human brain tissues.
Borsini, F; Cassano, GB; Giannaccini, G; Giromella, A; Lucacchini, A; Marazziti, D; Mazzoni, MR; Naccarato, AG; Palego, L, 1999
)
0.3
" There was a significant decrease with age in the maximal relaxation to cholera toxin as well as a rightward shift in the dose-response curve."( Impaired cholera toxin relaxation with age in rat aorta.
Chapman, J; Mader, SL; Schutzer, WE; Watts, VJ, 1999
)
0.3
" Dose-response curves in these studies suggest that Leydig cells of Djungarian hamsters undergo desensitization, probably due to down regulation of their LH/CG receptors."( Isolation method of Leydig cells from mature male Djungarian hamsters (Phodopus sungorus) and their steroidogenic activity in vitro.
Lerchl, A; Niedziela, M, 1999
)
0.3
" Forskolin (1 microM) caused hyperpolarization and a leftward shift in the dose-response relationship for Ba2+, suggesting that forskolin may activate a Ba2+-sensitive conductance."( Inward rectifier potassium conductance regulates membrane potential of canine colonic smooth muscle.
Bradley, KK; Flynn, ER; Hegarty, TM; Horowitz, B; Koh, SD; McManus, CA; Sanders, KM, 1999
)
0.3
" In dose-response experiments using the cAMP-analogue 8-(4-chlorophenylthio)-cAMP transepithelial electrical resistances were observed to increase above a threshold concentration ranging between 10(-5."( Barrier function of porcine choroid plexus epithelial cells is modulated by cAMP-dependent pathways in vitro.
Galla, HJ; Hakvoort, A; Wegener, J, 2000
)
0.31
" This effect was intensity-dependent (the sigmoidal dose-response curve was characterized by an EI(50) of 662+/-69 microT and a maximal increase of 321+/-13% of the control K(d)), reversible, temperature-dependent and specific to the 5-HT(1B) receptors."( Magnetic field desensitizes 5-HT(1B) receptor in brain: pharmacological and functional studies.
Bailly, JM; Deschamps, F; Fillion, G; Grimaldi, B; Kochanek, M; Lambrozo, J; Massot, O, 2000
)
0.31
" However, in Lewis rats amphetamine treatment increased the dose-response curve of forskolin stimulation."( Different activity of adenylyl cyclase in prefrontal cortex in three rat strains. The effect of amphetamine.
Hynie, S; Klenerová, V; Sída, P, 1998
)
0.3
" Once DeltaF508-CFTR channels were maximally activated with PKA, the mutant channel and WT channel had indistinguishable steady-state Po values, ATP dose-response relationships and single-channel kinetics, indicating that DeltaF508-CFTR is not defective in ATP-dependent gating."( Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels.
Hu, S; Hwang, TC; Wang, F; Zeltwanger, S, 2000
)
0.31
" alpha-MSH peptides were found to inhibit the stimulated GPx activity and had biphasic dose-response curves."( Alpha-melanocyte-stimulating hormone reduces impact of proinflammatory cytokine and peroxide-generated oxidative stress on keratinocyte and melanoma cell lines.
Cartledge, S; Ghanem, G; Haycock, JW; MacNeil, S; Morandini, R; Rennie, IG; Rowe, SJ; Wyatt, A, 2000
)
0.31
" Co-culture with diazoxide left-shifted the insulin dose-response to a cAMP analogue 5,6-dichloro-1-beta-d> -ribofuranosyl-benzimidazole-3',5'-cyclic monophosphorothioate."( Relief from glucose-induced over-stimulation sensitizes the adenylate cyclase-cAMP system of rat pancreatic islets.
Björklund, A; Grill, VE, 2000
)
0.31
" The Ca(2+) response occurred in all-or-none fashion and the half-maximal dosage of U50488H (812."( Cyclic AMP regulates the calcium transients released from IP(3)-sensitive stores by activation of rat kappa-opioid receptors expressed in CHO cells.
Allen, CN; Grandy, DK; Ikeda, M; Nelson, CS; Shinagawa, H; Shinoe, T; Sugiyama, T; Yoshioka, T, 2001
)
0.31
" Phorbol dibutyrate (PDB), an activator of protein kinase C, stimulated basal phospholipid methylation and also shifted the dose-response curve for dopamine-stimulated phospholipid methylation to the right by more than an order of magnitude."( Protein kinase C regulates dopamine D4 receptor-mediated phospholipid methylation.
Deth, RC; Sharma, A; Waly, M, 2001
)
0.31
" The dose-response curve for Zn(2+) inhibition was identical for AC1, AC5, and AC6 as well as for the C441R mutant of AC5 whose defect appears to be in one of the catalytic metal binding sites."( Zinc inhibition of cAMP signaling.
Heyduk, T; Howlett, AC; Hudson, TY; Klein, C; Sunahara, RK, 2002
)
0.31
"3x or 1x the maximum tolerated dosage (MTD: 45, 127 and 279 mg/kg for 7-day, 21-day and 90-day rats, respectively)."( Age-related effects of chlorpyrifos on muscarinic receptor-mediated signaling in rat cortex.
Liu, J; Pope, CN; Zhang, H, 2002
)
0.31
" The levels of activin betaA and ActRIIA receptor mRNA elevated with increasing dose of hCG; however, the effect significantly decreased at dosage higher than 15 IU/ml."( Gonadotropin regulation of activin betaA and activin type IIA receptor expression in the ovarian follicle cells of the zebrafish, Danio rerio.
Ge, W; Pang, Y, 2002
)
0.31
" Moreover, ACh and Ca(2+) dose-response studies showed that accumulation of cAMP shifted the dose-response curves to the low concentration side, suggesting that it increases Ca(2+) sensitivity in the fusion of the exocytotic cycle."( cAMP modulation of Ca(2+)-regulated exocytosis in ACh-stimulated antral mucous cells of guinea pig.
Fujiwara, S; Imai, Y; Katsu, K; Kojima, K; Nakahari, T; Shimamoto, C, 2002
)
0.31
" Analysis of dose-response curves to Ang III in forskolin-treated CTAL demonstrated that the maximal [Ca2+]i response was significantly increased without altering the EC50."( Potentiation of [Ca2+]i response to angiotensin III by cAMP in cortical thick ascending limb.
Corvol, P; Hus-Citharel, A; Llorens-Cortes, C; Marchetti, J, 2002
)
0.31
" In this report, we show that ATP elicits Ca(2+) responses producing a monophasic dose-response curve with an EC(50) value of 24."( GABAB receptor-mediated presynaptic potentiation of ATP ionotropic receptors in rat midbrain synaptosomes.
Gómez-Villafuertes, R; Gualix, J; Miras-Portugal, MT; Pintor, J, 2003
)
0.32
" Dose-response curves were constructed for the chorion cell cultures with CRH or 8-bromo-cAMP."( Regulation of 15-hydroxy prostaglandin dehydrogenase by corticotrophin-releasing hormone through a calcium-dependent pathway in human chorion trophoblast cells.
Challis, JR; McKeown, KJ, 2003
)
0.32
" Insulin responsiveness of the lipolytic and lipogenic pathways was analyzed by dose-response experiments, giving evidence for the involvement of improved insulin responsiveness in the enhanced lipogenic and reduced lipolytic activities of adipocytes in early pregnancy."( Fat accumulation in the rat during early pregnancy is modulated by enhanced insulin responsiveness.
Cacho, J; Crespo-Solans, MD; del Campo, S; Herrera, E; Ramos, MP, 2003
)
0.32
" We investigated the pharmacokinetics of colforsin daropate in cardiac surgery patients and performed simulations to determine the dosage necessary to maintain an effective plasma concentration following cardiopulmonary bypass."( Pharmacokinetics and a simulation model of colforsin daropate, new forskolin derivative inotropic vasodilator, in patients undergoing coronary artery bypass grafting.
Kikura, M; Morita, K; Sato, S, 2004
)
0.85
" All three agents denoted similar cAMP maximal responses in dose-response experiments."( The time-course of cyclic AMP signaling is critical for leukemia U-937 cell differentiation.
Baldi, A; Davio, C; Fernández, N; Legnazzi, BL; Monczor, F; Riveiro, ME; Shayo, C, 2004
)
0.32
" In control (missense ODN treated) rats, forskolin elicited a leftward shift in the SNAP dose-response curves (approximately 50% reduction in SNAP EC50)."( cAMP modulates cGMP-mediated cerebral arteriolar relaxation in vivo.
Baughman, VL; Gavrilyuk, V; Pelligrino, DA; Wolde, HM; Xu, HL, 2004
)
0.32
" With the current data the focus is on a time-course experiment; however, the proposed methods can easily be implemented on a dose-response experiment, or any other microarray experiment that contains a continuous variable of interest."( Empirical bayes gene screening tool for time-course or dose-response microarray data.
Burgoon, LD; Chinchilli, VM; Eckel, JE; Gennings, C; Zacharewski, TR, 2004
)
0.32
" In the present study, comparison of dose-response relations for hyperalgesia produced by PGE2, forskolin, 8-Br-cAMP, or the protein kinase A (PKA) catalytic subunit, in primed versus normal animals, demonstrated that priming-induced enhancement of the PGE2-activated second messenger cascade occurs downstream to adenylate cyclase and upstream to PKA."( Chronic hyperalgesic priming in the rat involves a novel interaction between cAMP and PKCepsilon second messenger pathways.
Levine, JD; Parada, CA; Reichling, DB, 2005
)
0.33
" Dose-response curves for isoproterenol on insulin background were also assessed in the presence and absence of a selective antagonist for beta(2)-adrenoceptor, ICI, at the dose of 5 x 10(-8) mol/L."( Insulin-induced changes in beta-adrenergic response: an experimental study in the isolated rat papillary muscle.
Abete, P; Cacciatore, F; Calabrese, C; Corbi, G; Ferrara, N; Iaccarino, G; Leosco, D; Longobardi, G; Paolisso, G; Rengo, F; Scarpa, D; Trimarco, B, 2005
)
0.33
" In vivo, dose-response studies in rats showed that at doses (i."( Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity.
Kapusta, DR; Kenigs, VA; Meier, E; Petersen, JS; Quist, C; Thorkildsen, C; Vinge, MM, 2005
)
0.33
" H-89, per se, did not modify glutamate release but reduced extracellular GABA value at the higher dosage used (200 microM)."( Differential roles of mGlu8 receptors in the regulation of glutamate and gamma-aminobutyric acid release at periaqueductal grey level.
de Novellis, V; Maione, S; Marabese, I; Mariani, L; Palazzo, E; Rodella, L; Rossi, F; Siniscalco, D, 2005
)
0.33
" This desensitization was not dependent on upregulation of cAMP-specific phosphodiesterases or changes in adenylate cyclase activity, as suggested by unaltered dose-response curves to agents directly affecting these enzymes."( Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs.
Breitenbach, SC; Ghofrani, HA; Grimminger, F; Kirchrath, JM; Nilius, SM; Pullamsetti, SS; Rose, F; Schermuly, RT; Schrör, K; Seeger, W; Weissmann, N, 2007
)
0.34
" Both 8-Br-cAMP (100 microM) and forskolin (10 microM) right-shifted the dose-response curves for the TRPM8-mediated effect of icilin and menthol on intracellular Ca(2+)."( Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids.
De Petrocellis, L; Di Marzo, V; Moriello, AS; Orlando, P; Starowicz, K; Vivese, M, 2007
)
0.34
" The dose-response curve for histamine is shifted to the left by approximately two orders of magnitude following 45 s pre-treatment with 1 microM PGE2."( Prostaglandin E2 sensitizes primary sensory neurons to histamine.
Bevan, S; Foster, AF; Nicolson, TA; Richards, CD, 2007
)
0.34
" The observation of gene dosage effects in transgenic mouse models implies that subtle changes in expression levels can affect the correct function of the DYRK1A gene product."( Characterization of the human DYRK1A promoter and its regulation by the transcription factor E2F1.
Becker, W; Galceran, J; Hekerman, P; Maenz, B; Vela, EM, 2008
)
0.35
" The cAMP-mobilizing compounds forskolin, vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC) agonists PACAP-38 and PACAP-27 had no effect on the dose-response curve."( Duck pancreatic acinar cell as a unique model for independent cholinergic stimulation-secretion coupling.
Cui, ZJ; Liang, HY; Wang, BJ, 2009
)
0.35
" The validated ELSD method permits a shorter determination time without compromising accuracy and demonstrates that it can be used for quantification of forskolin incorporated in multi-herbal solid oral dosage forms."( A rapid HPLC with evaporative light scattering method for quantification of forskolin in multi-herbal weight-loss solid oral dosage forms.
Taki, Y; Umegaki, K; Virgona, N, 2010
)
0.36
" Curcumin slowed cyst enlargement in both MDCK cyst model and embryonic kidney cyst model with dose-response relationship."( Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways.
Gao, J; Lei, T; Li, W; Li, X; Yang, B; Zhou, H; Zhou, L, 2011
)
0.37
" Dose-response curves were obtained for the correlation between hormone concentrations and the concentration of the individual disruptors."( Corticosteroid production in H295R cells during exposure to 3 endocrine disrupters analyzed with LC-MS/MS.
Hansen, M; Nielsen, FK; Styrishave, B; Winther, CS,
)
0.13
" Here we illustrate a protocol to calibrate the response detected by different targeted FRET reporters involving the generation of a dose-response curve to the cAMP raising agent forskolin."( Analysis of compartmentalized cAMP: a method to compare signals from differently targeted FRET reporters.
Fields, LA; Jiang, H; Koschinski, A; Stangherlin, A; Terrin, A; Zaccolo, M; Zoccarato, A, 2014
)
0.4
" Cells incubated with the cAMP permeable analog dibutyryl cyclic AMP (db-cAMP: 1,10,100 μM) for 48 h exhibited a dose-response increase in GST class α and MRP2 protein expression."( Coordinated induction of GST and MRP2 by cAMP in Caco-2 cells: Role of protein kinase A signaling pathway and toxicological relevance.
Arana, MR; Arias, A; Banchio, C; Domizi, P; Luquita, MG; Mottino, AD; Rigalli, JP; Ruiz, ML; Tocchetti, GN; Villanueva, SSM, 2015
)
0.42
" Last, OMP also steepens the dose-response relation to improve concentration coding although at the cost of losing responses to weak stimuli."( The Odorant Receptor-Dependent Role of Olfactory Marker Protein in Olfactory Receptor Neurons.
Dibattista, M; Reisert, J, 2016
)
0.43
" In order to obtain better insights into the processes of steroidogenesis, we investigated the dose-response relationship of forskolin, an activator of adenylate cyclase, on steroid production in H295R cells."( LC-MS/MS based profiling and dynamic modelling of the steroidogenesis pathway in adrenocarcinoma H295R cells.
Ahmed, KEM; Frøysa, HG; Goksøyr, A; Karlsen, OA; Kellmann, R; Mellgren, G; Ropstad, E; Sagen, JV; Verhaegen, S, 2018
)
0.48
" Although the increase in dosage of certain genes on chromosome 21 has been associated with the DS phenotype, the effects on placenta have seldom been studied."( Amyloid Precursor Protein Overexpression in Down Syndrome Trophoblast Reduces Cell Invasiveness and Interferes with Syncytialization.
Cheung, ANY; Cheung, CLY; Ip, PPC; Ngan, HYS; Wong, OGW, 2018
)
0.48
" Cilostamide at the high dosage (20 μM) also upregulated GJA1 expression."( Cilostamide and forskolin maintain gap junction function of incubated dog follicles.
Brown, M; Chansaenroj, A; Doriguzzi, N; Nagashima, J; Songsasen, N; Thongkittidilok, C, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
anti-HIV agentAn antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus.
protein kinase A agonistA protein kinase agonist that selectively binds to and activates a protein kinase A receptor
adenylate cyclase agonistAny agonist of one or more of the isoforms of adenylate cyclase (EC 4.6.1.1).
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
labdane diterpenoidAny diterpenoid with a labdane skeleton.
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
triolA chemical compound containing three hydroxy groups.
cyclic ketone
tertiary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (54)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency1.69660.01846.806014.1254AID624172; AID743262
pregnane X receptorRattus norvegicus (Norway rat)Potency7.94330.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency31.48060.006038.004119,952.5996AID1159521; AID1159523
TDP1 proteinHomo sapiens (human)Potency17.26130.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.06590.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency13.13330.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency42.16600.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency25.66530.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency0.21690.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency12.11710.01237.983543.2770AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.54680.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency34.08110.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency16.80680.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency2.85190.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency34.23000.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency14.75940.005428.02631,258.9301AID1346982; AID1346985; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.97620.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency32.48300.01238.964839.8107AID1645842
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency5.00770.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency0.12590.001019.414170.9645AID588536
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.00440.023723.228263.5986AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency19.73640.000723.06741,258.9301AID651777; AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency1.07860.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.06400.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259393
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency5.01190.10009.191631.6228AID1346983
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.03660.000323.4451159.6830AID743065; AID743067
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency10.00000.010323.856763.0957AID2662
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency30.64210.000627.21521,122.0200AID651741; AID720636
gemininHomo sapiens (human)Potency23.10930.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.53440.005612.367736.1254AID624032; AID624044
relaxin receptor 1 isoform 1Homo sapiens (human)Potency0.03880.038814.350143.6206AID489012
relaxin receptor 2 isoform 1Homo sapiens (human)Potency0.04880.048815.980148.9431AID489043
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency11.42650.001557.789015,848.9004AID1259244
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency100.00006.309660.2008112.2020AID720707
Interferon betaHomo sapiens (human)Potency32.48300.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency32.48300.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency0.48560.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency11.42650.001551.739315,848.9004AID1259244
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency32.48300.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.23010.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency0.19400.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency32.48300.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor subfamily 0 group B member 1Homo sapiens (human)IC50 (µMol)1.72900.13430.86462.1450AID687017
steroidogenic factor 1Homo sapiens (human)IC50 (µMol)67.54701.87302.92953.9860AID687018
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)134.20000.00022.318510.0000AID681127; AID681131
5-hydroxytryptamine receptor 1AHomo sapiens (human)IC50 (µMol)0.04100.00010.666410.0000AID34749
Adenylate cyclase type 1Homo sapiens (human)IC50 (µMol)0.09550.04100.09550.1500AID34749; AID34754
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)6.35000.00203.519610.0000AID1215085; AID1215086; AID1215087; AID1215094
Solute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)Kd5.00005.00005.00005.0000AID74401
Adenylate cyclase type 2Rattus norvegicus (Norway rat)EC50 (µMol)2.00000.07101.03552.0000AID32785
Adenylate cyclase type 8Homo sapiens (human)EC50 (µMol)0.09370.07100.08240.0937AID1646831
Adenylate cyclase type 1Homo sapiens (human)EC50 (µMol)0.50000.07100.28550.5000AID34748
Relaxin receptor 1Homo sapiens (human)EC50 (µMol)0.04700.04700.04700.0470AID1361398
Nuclear receptor subfamily 1 group I member 2Rattus norvegicus (Norway rat)EC50 (µMol)7.10000.01004.139410.0000AID1215090
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (291)

Processvia Protein(s)Taxonomy
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
central nervous system developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to hypoxiaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pregnancySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
long-chain fatty acid import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
L-ascorbic acid metabolic processSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cerebral cortex developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to glucose starvationSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor cell maintenanceSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein-containing complex assemblySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to mechanical stimulusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular hyperosmotic responseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to Thyroglobulin triiodothyronineSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose importSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to insulinSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
signal transductionAdenylate cyclase type 8Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAdenylate cyclase type 8Homo sapiens (human)
learning or memoryAdenylate cyclase type 8Homo sapiens (human)
memoryAdenylate cyclase type 8Homo sapiens (human)
long-term memoryAdenylate cyclase type 8Homo sapiens (human)
locomotory behaviorAdenylate cyclase type 8Homo sapiens (human)
glucose mediated signaling pathwayAdenylate cyclase type 8Homo sapiens (human)
positive regulation of synaptic plasticityAdenylate cyclase type 8Homo sapiens (human)
positive regulation of CREB transcription factor activityAdenylate cyclase type 8Homo sapiens (human)
activation of protein kinase A activityAdenylate cyclase type 8Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 8Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusAdenylate cyclase type 8Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwayAdenylate cyclase type 8Homo sapiens (human)
glucose homeostasisAdenylate cyclase type 8Homo sapiens (human)
regulation of insulin secretionAdenylate cyclase type 8Homo sapiens (human)
protein complex oligomerizationAdenylate cyclase type 8Homo sapiens (human)
protein homooligomerizationAdenylate cyclase type 8Homo sapiens (human)
regulation of cytosolic calcium ion concentrationAdenylate cyclase type 8Homo sapiens (human)
cellular response to calcium ionAdenylate cyclase type 8Homo sapiens (human)
cellular response to morphineAdenylate cyclase type 8Homo sapiens (human)
cellular response to glucose stimulusAdenylate cyclase type 8Homo sapiens (human)
cellular response to glucagon stimulusAdenylate cyclase type 8Homo sapiens (human)
regulation of cellular response to stressAdenylate cyclase type 8Homo sapiens (human)
neuroinflammatory responseAdenylate cyclase type 8Homo sapiens (human)
positive regulation of long-term synaptic potentiationAdenylate cyclase type 8Homo sapiens (human)
positive regulation of long-term synaptic depressionAdenylate cyclase type 8Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 8Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 8Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 8Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 1Homo sapiens (human)
axonogenesisAdenylate cyclase type 1Homo sapiens (human)
long-term memoryAdenylate cyclase type 1Homo sapiens (human)
circadian rhythmAdenylate cyclase type 1Homo sapiens (human)
response to xenobiotic stimulusAdenylate cyclase type 1Homo sapiens (human)
cAMP-mediated signalingAdenylate cyclase type 1Homo sapiens (human)
positive regulation of CREB transcription factor activityAdenylate cyclase type 1Homo sapiens (human)
regulation of circadian rhythmAdenylate cyclase type 1Homo sapiens (human)
cellular response to calcium ionAdenylate cyclase type 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenylate cyclase type 1Homo sapiens (human)
neuroinflammatory responseAdenylate cyclase type 1Homo sapiens (human)
positive regulation of long-term synaptic potentiationAdenylate cyclase type 1Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 1Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
parturitionRelaxin receptor 1Homo sapiens (human)
extracellular matrix organizationRelaxin receptor 1Homo sapiens (human)
myofibroblast differentiationRelaxin receptor 1Homo sapiens (human)
lung connective tissue developmentRelaxin receptor 1Homo sapiens (human)
nipple morphogenesisRelaxin receptor 1Homo sapiens (human)
hormone-mediated signaling pathwayRelaxin receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRelaxin receptor 1Homo sapiens (human)
activation of adenylate cyclase activityRelaxin receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (91)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
long-chain fatty acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
kinase bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
identical protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
D-glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
actin bindingAdenylate cyclase type 8Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 8Homo sapiens (human)
calmodulin bindingAdenylate cyclase type 8Homo sapiens (human)
ATP bindingAdenylate cyclase type 8Homo sapiens (human)
calcium- and calmodulin-responsive adenylate cyclase activityAdenylate cyclase type 8Homo sapiens (human)
protein homodimerization activityAdenylate cyclase type 8Homo sapiens (human)
metal ion bindingAdenylate cyclase type 8Homo sapiens (human)
protein heterodimerization activityAdenylate cyclase type 8Homo sapiens (human)
protein dimerization activityAdenylate cyclase type 8Homo sapiens (human)
protein phosphatase 2A bindingAdenylate cyclase type 8Homo sapiens (human)
calmodulin bindingAdenylate cyclase type 1Homo sapiens (human)
ATP bindingAdenylate cyclase type 1Homo sapiens (human)
calcium- and calmodulin-responsive adenylate cyclase activityAdenylate cyclase type 1Homo sapiens (human)
metal ion bindingAdenylate cyclase type 1Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 1Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
G protein-coupled receptor activityRelaxin receptor 1Homo sapiens (human)
protein bindingRelaxin receptor 1Homo sapiens (human)
hormone bindingRelaxin receptor 1Homo sapiens (human)
metal ion bindingRelaxin receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityRelaxin receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (79)

Processvia Protein(s)Taxonomy
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Golgi membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female germ cell nucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor inner segmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pronucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cytosolSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
caveolaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
intercalated discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Z discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
midbodySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cortical actin cytoskeletonSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
sarcolemmaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
melanosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
extracellular exosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
blood microparticleSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
presynapseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transporter complexSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
actin cytoskeletonAdenylate cyclase type 8Homo sapiens (human)
plasma membraneAdenylate cyclase type 8Homo sapiens (human)
caveolaAdenylate cyclase type 8Homo sapiens (human)
clathrin-coated pitAdenylate cyclase type 8Homo sapiens (human)
postsynaptic densityAdenylate cyclase type 8Homo sapiens (human)
membraneAdenylate cyclase type 8Homo sapiens (human)
basolateral plasma membraneAdenylate cyclase type 8Homo sapiens (human)
apical plasma membraneAdenylate cyclase type 8Homo sapiens (human)
axonAdenylate cyclase type 8Homo sapiens (human)
dendriteAdenylate cyclase type 8Homo sapiens (human)
clathrin-coated vesicle membraneAdenylate cyclase type 8Homo sapiens (human)
neuronal cell body membraneAdenylate cyclase type 8Homo sapiens (human)
presynaptic membraneAdenylate cyclase type 8Homo sapiens (human)
plasma membrane raftAdenylate cyclase type 8Homo sapiens (human)
membrane raftAdenylate cyclase type 8Homo sapiens (human)
presynaptic active zoneAdenylate cyclase type 8Homo sapiens (human)
excitatory synapseAdenylate cyclase type 8Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenylate cyclase type 8Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseAdenylate cyclase type 8Homo sapiens (human)
glutamatergic synapseAdenylate cyclase type 8Homo sapiens (human)
plasma membraneAdenylate cyclase type 8Homo sapiens (human)
cytoplasmAdenylate cyclase type 1Homo sapiens (human)
plasma membraneAdenylate cyclase type 1Homo sapiens (human)
membrane raftAdenylate cyclase type 1Homo sapiens (human)
extracellular exosomeAdenylate cyclase type 1Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenylate cyclase type 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseAdenylate cyclase type 1Homo sapiens (human)
presynapseAdenylate cyclase type 1Homo sapiens (human)
postsynaptic density membraneAdenylate cyclase type 1Homo sapiens (human)
glutamatergic synapseAdenylate cyclase type 1Homo sapiens (human)
plasma membraneAdenylate cyclase type 1Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
plasma membraneRelaxin receptor 1Homo sapiens (human)
plasma membraneRelaxin receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (151)

Assay IDTitleYearJournalArticle
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID297148Inhibition of SARS virus-induced cytopathogenicity in Vero E6 cells at 1 uM2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID91116Compound was testd for inhibition of glucose transport human erythrocytes using [H]-forskolin as radioligand1999Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13
On the analogy between forskolin and D-glucose.
AID34748Conversion of [32P] ATP to [32P]-cyclic AMP mediated by adenylate cyclase 11996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Forskolin carbamates: binding and activation studies with type I adenylyl cyclase.
AID1361398Agonist activity at human RXFP1 expressed in HEK293 cells assessed as increase in cAMP accumulation after 30 mins by HTRF assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile.
AID297151Selectivity index, Ratio of CC50 for Vero E6 cells to EC50 for SARS coronavirus2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID1215086Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID513640Induction of autophagy in rat stable inducible PC12 cells expressing A53T alpha-synuclein assessed as A53T alpha-synuclein clearance at 500 uM after 24 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID524989Inhibition of HDAC7 in wild-type CFTR expressing human primary lung cells assessed as induction of short circuit currents at 1 uM for 4, 6, and 8 days relative to control2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID334315Induction of morphological transformation of rat ASK cells into astrocytes at 0.5 uM after 1 hr by light microscopy
AID1646831Agonist activity at recombinant human AC8 expressed in human HEK293 cells assessed as fold increase in cAMP level by LANCE Ultra cAMP Detection kit method2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Discovery of a potent and selective adenylyl cyclase type 8 agonist by docking-based virtual screening.
AID34754Inhibition of [125 I]6-IHPP-forskolin binding to Adenylate cyclase 11996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Forskolin carbamates: binding and activation studies with type I adenylyl cyclase.
AID1215090Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID681126TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID334312Induction of morphological transformation of rat ASK cells into astrocytes at 0.004 uM after 1 hr by light microscopy
AID334316Induction of morphological transformation of rat ASK cells into astrocytes at 2.5 uM after 1 hr by light microscopy
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1215097Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to dexamethasone2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID55246Percent activation of wild type CFTR dependent efflux was determined by measuring the rate of iodide [125I]- efflux from transfected CHO cells2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels.
AID1532838Induction of membrane translocation of biotinylated human AQP2 expressed in rat IMCD cells at 100 uM after 30 mins by FITC-staining based confocal fluorescence microscopic analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance.
AID155127Cytotoxicity in HPBMC (Human Peripheral Blood Mononuclear Cells); Not active2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Synthesis of a novel family of diterpenes and their evaluation as anti-inflammatory agents.
AID1388210Antiproliferative activity against human MCF7 cells after 48 hrs by Alamar blue assay2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis of novel forskolin isoxazole derivatives with potent anti-cancer activity against breast cancer cell lines.
AID1261230Agonist activity at human TGR5 E169A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level at 10 uM incubated for 16 hrs by luciferase reporter assay relative to wild type2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID34162Displacement of [125I]6-IHPP-Fsk from adenylate cyclase of bovine brain membrane1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
(Aminoalkyl)carbamates of forskolin: intermediates for the synthesis of functionalized derivatives of forskolin with different specificities for adenylyl cyclase and the glucose transporter.
AID155130Inhibition efficacy of TNF-alpha was tested in HPBMC (Human Peripheral Blood Mononuclear Cells); Not active2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Synthesis of a novel family of diterpenes and their evaluation as anti-inflammatory agents.
AID297149Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID32785Ability to activate the conversion of [32P] ATP to [32P]-cyclic AMP1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Forskolin carbamates: binding and activation studies with type I adenylyl cyclase.
AID1215094Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID524992Inhibition of HDAC7 in wild-type CFTR expressing human primary lung cells assessed as forskolin-stimulated Fdelta508 CFTR channel activity at 10 uM after 24 hrs relative to control2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID681127TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID1215096Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID423638Permeability across human skin assessed as cumulative drug content applied topically after 24 hrs by LC-MS analysis2009Journal of natural products, Apr, Volume: 72, Issue:4
In vitro skin diffusion study of pure forskolin versus a forskolin-containing Plectranthus barbatus root extract.
AID334314Induction of morphological transformation of rat ASK cells into astrocytes at 0.10 uM after 1 hr by light microscopy
AID338162Displacement of [3H]forskolin from forskolin site of adenylate cyclase1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID1215085Activation of PXR in human cryopreserved hepatocytes assessed as induction of CYP3A42011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID157580Cytotoxicity in HPBMC (Human Peripheral Blood Mononuclear Cells); Not tested2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Synthesis of a novel family of diterpenes and their evaluation as anti-inflammatory agents.
AID155451Inhibition of TNF-alpha was tested in HPBMC (Human Peripheral Blood Mononuclear Cells); inactive2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Synthesis of a novel family of diterpenes and their evaluation as anti-inflammatory agents.
AID334313Induction of morphological transformation of rat ASK cells into astrocytes at 0.02 uM after 1 hr by light microscopy
AID34749Inhibition of [125 I]6-IHPP-forskolin binding to adenylate cyclase 11996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Forskolin carbamates: binding and activation studies with type I adenylyl cyclase.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1491073Activation of PGC1alpha transcriptional activity (unknown origin) expressed in HEK293 cells at 5 uM after 24 hrs by luciferase reporter gene assay relative to control2017Journal of natural products, 05-26, Volume: 80, Issue:5
Cucurbitane Glucosides from the Crude Extract of Siraitia grosvenorii with Moderate Effects on PGC-1α Promoter Activity.
AID47796Effective dose for lowering blood pressure in anesthetized cat when administered intravenously1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Cardiovascular effects of new water-soluble derivatives of forskolin.
AID423643Permeability flux across guinea pig skin applied topically after 24 hrs by LC-MS analysis2009Journal of natural products, Apr, Volume: 72, Issue:4
In vitro skin diffusion study of pure forskolin versus a forskolin-containing Plectranthus barbatus root extract.
AID423639Permeability flux across human skin applied topically after 24 hrs by LC-MS analysis2009Journal of natural products, Apr, Volume: 72, Issue:4
In vitro skin diffusion study of pure forskolin versus a forskolin-containing Plectranthus barbatus root extract.
AID423637Permeability across human skin assessed as drug content per gram of wet tissue applied topically after 24 hrs by LC-MS analysis2009Journal of natural products, Apr, Volume: 72, Issue:4
In vitro skin diffusion study of pure forskolin versus a forskolin-containing Plectranthus barbatus root extract.
AID334311Induction of morphological transformation of rat ASK cells into astrocytes after 1 hr by light microscopy
AID297145Inhibition of SARS coronavirus-induced cytopathogenicity in Vero E6 cells at 20 uM2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID1532836Induction of membrane translocation of biotinylated human AQP2 expressed in rat IMCD cells at 100 uM after 30 mins by Western blot analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance.
AID1215087Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID92670Compound was testd for inhibition of glucose transport human platelets using [H]-forskolin as radioligand1999Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13
On the analogy between forskolin and D-glucose.
AID338199Displacement of [3H]forskolin from forskolin site of adenylate cyclase assessed as specific binding relative to total binding1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID566358Stimulation of rat adenylate cyclase2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID34591Effect of compound on cellular c-AMP levels by activation of Adenylate cyclase2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Benzyloxybenzaldehyde analogues as novel adenylyl cyclase activators.
AID524990Inhibition of HDAC7 in human homozygous Fdelta508 primary bronchial epithelial cells assessed as induction of short circuit currents at 1 uM for 4, 6, and 8 days relative to control2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID681131TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID423642Permeability across guinea pig skin assessed as cumulative drug content applied topically after 24 hrs by LC-MS analysis2009Journal of natural products, Apr, Volume: 72, Issue:4
In vitro skin diffusion study of pure forskolin versus a forskolin-containing Plectranthus barbatus root extract.
AID755630Activation of human BKCA alpha channel expressed in HEK293 cells assessed as increase in intracellular calcium level at 50 uM after 30 mins2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Large conductance Ca(2+)-activated K(+) channel (BKCa) activating properties of a series of novel N-arylbenzamides: Channel subunit dependent effects.
AID303513Activation of TGR5 expressed in HEK293 cells assessed as elevation of cAMP production at 100 uM relative to control2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID423645Ratio of permeability flux across guinea pig skin to permeability flux across human skin2009Journal of natural products, Apr, Volume: 72, Issue:4
In vitro skin diffusion study of pure forskolin versus a forskolin-containing Plectranthus barbatus root extract.
AID1215095Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay relative to SR128132011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID86815Percent increase in the Forskolin-Stimulated cAMP formation, in HeLa cells transfected with the 5-HT 1A receptor at 10 uM concentration2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
AID59650Dose required to produce 50 % increase in left ventricular dP/dt max in anesthetized dogs when administered intravenously1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Cardiovascular effects of new water-soluble derivatives of forskolin.
AID1388212Cytotoxicity against human MCF7 cells assessed as morphological changes after 48 hrs by microscopic analysis2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis of novel forskolin isoxazole derivatives with potent anti-cancer activity against breast cancer cell lines.
AID423644Permeability across guinea pig skin assessed as permeation lag time applied topically after 24 hrs by LC-MS analysis2009Journal of natural products, Apr, Volume: 72, Issue:4
In vitro skin diffusion study of pure forskolin versus a forskolin-containing Plectranthus barbatus root extract.
AID423641Permeability across guinea pig skin assessed as drug content per gram of wet tissue applied topically after 24 hrs by LC-MS analysis2009Journal of natural products, Apr, Volume: 72, Issue:4
In vitro skin diffusion study of pure forskolin versus a forskolin-containing Plectranthus barbatus root extract.
AID34753Maximum stimulation activity measured with 100 uM forskolin mediated by adenylate cyclase 11996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Forskolin carbamates: binding and activation studies with type I adenylyl cyclase.
AID513641Induction of autophagy in human SK-N-SH cells expressing EGFP-HDQ74 assessed as reduction in EGFP-HDQ74 aggregation at 500 uM after 48 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID1138165Induction of cAMP production in GP-BAR1-deficient HEK293T cells at 10 uM by cAMP responsive element containing luciferase reporter gene assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.
AID134238Acute toxicity in mice when administered intraperitoneally1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Cardiovascular effects of new water-soluble derivatives of forskolin.
AID1646832Agonist activity at recombinant human AC8 expressed in human HEK293 cells assessed as fold increase in cAMP level at 50 uM by LANCE Ultra cAMP Detection kit method relative to control2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Discovery of a potent and selective adenylyl cyclase type 8 agonist by docking-based virtual screening.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID231756Ratio of cAMP-elevating activity relative to forskolin2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Benzyloxybenzaldehyde analogues as novel adenylyl cyclase activators.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID524991Inhibition of HDAC7 in human homozygous Fdelta508 primary bronchial epithelial cells assessed as increase in short circuit currents at 1 uM for 4, 6, and 8 days relative to control2010Nature chemical biology, Jan, Volume: 6, Issue:1
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID73905Positive inotropic activity in spontaneously beating guinea pig atria1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Cardiovascular effects of new water-soluble derivatives of forskolin.
AID87449Effect on Forskolin-Stimulated cAMP formation, in HeLa cells transfected with the 5-HT 1A receptor at 10 uM concentration2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
AID205269Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID74401Inhibition of [125I]7-IHPP-Fsk binding to glucose transporter of human erythrocyte membrane1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
(Aminoalkyl)carbamates of forskolin: intermediates for the synthesis of functionalized derivatives of forskolin with different specificities for adenylyl cyclase and the glucose transporter.
AID1215089Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID297150Cytotoxicity against Vero E6 cells by MTT assay2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID297147Inhibition of SARS virus-induced cytopathogenicity in Vero E6 cells at 3.3 uM2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID175489Compound was tested for inhibition of glucose transport in adipocytes plasma membrane vesicles using [H]-forskolin as radioligand1999Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13
On the analogy between forskolin and D-glucose.
AID1491071Activation of PGC1alpha transcriptional activity (unknown origin) expressed in HEK293 cells at 5 uM after overnight incubation by luciferase reporter gene assay relative to control2017Journal of natural products, 05-26, Volume: 80, Issue:5
Cucurbitane Glucosides from the Crude Extract of Siraitia grosvenorii with Moderate Effects on PGC-1α Promoter Activity.
AID423640Permeability across human skin assessed as permeation lag time applied topically after 24 hrs by LC-MS analysis2009Journal of natural products, Apr, Volume: 72, Issue:4
In vitro skin diffusion study of pure forskolin versus a forskolin-containing Plectranthus barbatus root extract.
AID297146Inhibition of SARS coronavirus-induced cytopathogenicity in Vero E6 cells at 10 uM2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID1388211Antiproliferative activity against human BT474 cells after 48 hrs by Alamar blue assay2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis of novel forskolin isoxazole derivatives with potent anti-cancer activity against breast cancer cell lines.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13,180)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902380 (18.06)18.7374
1990's5894 (44.72)18.2507
2000's3398 (25.78)29.6817
2010's1292 (9.80)24.3611
2020's216 (1.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.76 (24.57)
Research Supply Index9.51 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index28.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials46 (0.34%)5.53%
Reviews101 (0.75%)6.00%
Case Studies17 (0.13%)4.05%
Observational1 (0.01%)0.25%
Other13,295 (98.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]